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CHAPTER 1 
Introduction 
1.1 Introduction to RNA  
Since discovery of the DNA double-helical structure, intensive research 
has focused on solving the mysteries of how the genetic information flows from 
DNA to cellular components (1). With establishment of the central dogma, RNA 
was identified as a key intermediate (Figure 1.1) (2, 3). The role of RNA in the 
cell life cycle was first recognized in protein synthesis (1-3). The information is 
delivered from DNA to protein by transcription and translation (1-3). Three 
types of RNA were first identified. Messenger RNA (mRNA) is a short-lived 
RNA species that carries the genetic information transcribed from DNA (1-3). 
Transfer RNAs (tRNAs) possess the second genetic code corresponding to 
various amino acids (1-3). The tRNA connects the nucleic acid and amino acid 
sequences (1-3). The ribosome is a large riboprotein assembly composed of 
multiple proteins and RNAs (4-6). The ribosome is the protein synthesis 
machinery responsible for translating information encoded by the mRNA to the 
polypeptide chain (4-6). The ribosome can be viewed as the working station, 
while mRNA is the template, and tRNA carries the building blocks. Recently 
obtained crystal structures of ribosomal particles demonstrated unambiguously 
that ribosomal RNA (rRNA) is the major actor in protein biosynthesis, since the 
active sites exclusively comprise RNA, and the fundamental steps involve 
RNA-RNA interactions (5-7).  
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Figure 1.1. A representative scheme of the central dogma (upper) and three types of 
RNA (lower) in protein synthesis, namely tRNA, rRNA (PDB: 2I2T and 2I2P) and mRNA, 
are shown. 
Messanger RNA can also undergo a maturation process, which is 
catalyzed by the RNA itself (8, 9). These catalytic RNAs are called ribozymes 
(8, 9). Moreover, novel regulatory roles of RNA in both transcription and 
translation have been revealed. Small interfering RNAs (siRNAs) and 
microRNAs (miRNAs) are 20-30 nucleotide-long, non-translated RNAs with 
regulatory functions (10, 11). The common action of siRNA and miRNA in gene 
regulation is that they recognize target mRNAs with complementary 
sequences, and further direct their destruction or inhibit their utilization in 
translation (10-12). Long non-coding RNA (lncRNA) further expanded the 
world of regulatory RNAs (13, 14). The lncRNAs are generally more than 200 
nucleotides long and regulate genes in a wide variety of important biological 
processes (1, 13-15). The biochemical nature of lncRNA regulation is still 
poorly understood (1, 13-15). New roles for RNA continue to emerge, and the 
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known biological functions of RNA continue to expand in scope (1, 13-15). 
RNA is recognized as an important player in all of molecular biology and is 
essential for cell survival.  
The linear sequence of RNA is built up from different ribonucleosides 
(adenosine, guanosine, cytidine, uridine) and their modified derivatives (16). 
RNA folds into a wide range of three-dimensional structures by following a 
hierarchical pathway analogous to that observed for proteins (17, 18). The 
primary structure dictates the type of secondary structure via complementary 
base pairing, which then leads to tertiary structure through multiple interactions 
between secondary structures (17, 18). The biochemical function of RNA is 
tightly connected to its conformation, and the folded structures create binding 
pockets similar to those of proteins for substrate or ligand recognition (19). The 
number of reports on detailed structures and functions of RNA, particularly 
rRNA, has grown rapidly over the past decade. With its crucial cellular roles 
and ability to form substrate-binding pockets, RNA has presented itself as an 
ideal target for drug discovery.  
 
1.2 The ribosome as a potential drug target  
1.2.1 Introduction to ribosomes 
As established in the central dogma, the ribosome was identified as the 
protein synthesis machinery (2, 3). Ribosomes are located in the cytoplasm (2, 
3). They are composed of multiple proteins and RNAs, with rRNA dominating  
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Figure 1.2. The ribosome is composed of two unequally sized assemblies, one large 
and one small subunit. Each subunit is also composed of ribosomal RNAs (bottom, left) 
and proteins (bottom, right) (PDB: 2I2T and 2I2P).  
the main functional steps (two-thirds of the ribosome is composed of RNA,  
Figure 1.2) (20). All ribosomes consist of two unequally sized assemblies, one 
large and one small subunit (Figure 1.2) (4). The small subunit is involved in 
the initiation step of translation and also controls fidelity in decoding the 
genetic information from mRNA (4). The large subunit catalyzes peptide-bond 
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formation, and also guides the newly synthesized protein chain through the 
dynamic exit tunnel (4). The rapid and precise assembly of the two subunits is 
important for accurate function (21, 22). The ribosome assembles in vivo 
through an intersubunit interface that relies heavily on RNA-RNA interactions 
(21, 22). The intersubunit bridges contribute to the maintenance and function 
of the assembled complex (4). Accurate conformational dynamics of the 
ribosome are indispensable for protein biosynthesis, which is necessary for 
any organism's survival. It is therefore not surprising that the ribosome has 
drawn great attention among various RNAs as an ideal drug target.  
 
1.2.2 The ribosome as a drug target in eukaryotic cells 
It is well known that most cancer cells possess hyper-proliferative behavior. 
In order to maintain their fast and unbridled growth, cancer cells require a 
global increase in protein synthesis. Excessive and hypoactive ribosomes are 
generally observed in cancer cells due to deregulated signaling (23, 24). It is 
now apparent that targeting the ribosome in cancer cells could be a powerful 
strategy in antitumor therapy. 
Cycloheximide (CHX) is one of the known glutarimide antibiotics that 
targets the eukaryotic ribosome (Figure 1.3A) (25). It inhibits protein 
biosynthesis by blocking the elongation phase and eEF2-mediated 
translocation (25, 26). As reported in 2010, the Shen and Liu groups used a 
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Figure 1.3. Chemical structures of ribosome-targeting antibiotics are shown. A) CHX 
and LTM target the E site of eukaryotic ribosome. B) Streptomycin was the 
first-discovered aminoglycoside-type antibiotic. Streptomycin and neomycin are 
decoding-site targeting antibiotics. C) Three macrolide-type antibiotics are shown.  
The large subunit of bacterial ribosome is their molecular target (27-30). The charges at 
pH 7.0 are indicated.  
cell-based screening assay to discover a CHX structural analogue, 
lactimidomycin (LTM) (Figure 1.3A), with potent antiproliferative activity (26). 
Similar to CHX, LTM maintains the glutarimide group, but has an added 
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12-membered macrocycle that was later shown to be essential for its activity 
(26). The in vitro study suggested that LTM is a better inhibitor than CHX, even 
though they have a common binding site at the E site of 60S rRNA (26). 
Further mouse experiments established the potential of LTM as an anticancer 
drug targeting tumor cell ribosomes (Figure 1.3A) (26). With increasing 
evidence pointing to the connection between protein synthesis and cancer cell 
growth, attention on cellular translation is rapidly increasing in cancer therapy 
(26). As a major cellular player, the placement of ribosomes on the list of 
potential antitumor therapeutic targets is reinforced.  
 
1.2.3 The ribosome as a drug target in bacteria 
In the history of antibacterial drug discovery, the ribosome holds its 
position as a highly validated and versatile target (31, 32). Approximately half 
of the antibiotic classes used in the clinic target ribosomes (31, 32). One of the 
most important antibiotic families is the aminoglycosides (Figure 1.3B) (28). 
Aminoglycosides were established as antibiotics when streptomycin was 
discovered in the 1940s (Figure 1.3B) (33, 34). Streptomycin has been widely 
used in treating bacterial infections, including Gram-positive and 
Gram-negative pathogens (33, 34). Its antibacterial mechanism has been well 
characterized, and 16S rRNA in the small subunit of bacterial ribosomes was 
identified as the molecular target (33).  
In addition to aminoglycosides, the macrolide family is also a well-known 
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group of antibiotics that use the bacterial ribosome as the pharmacological 
target (Figure 1.3C) (29, 30). Macrolides bind to the large subunit of the 
bacterial ribosome and inhibit peptide transfer and translocation (30). Due to 
high affinity to bacterial ribosomes combined with high structural conservation 
of ribosomes across virtually all of the bacterial families, macrolides 
demonstrate broad-spectrum antibacterial activity (30). Ribosome-targeting 
antimicrobials have already demonstrated their therapeutic effects in treating 
bacterial infections (32). In addition to their toxicity against bacteria, these 
compounds also present a surprising selectivity for bacterial targets because 
of different transport efficiencies with higher organisms (32).  
 
1.2.4 The ribosome and antibiotic resistance 
During the 1960s, antibiotic research reached its golden age. It was once 
believed that the bacterial infection was completely defeated by these miracle 
small molecules. Unfortunately, due to their excessive and heavy clinical 
usage, many bacterial strains have developed resistance to the antibiotics on 
the market (35, 36). There has been a steady increase in the emergence of 
multi-antibiotic-resistant pathogenic bacteria in the last few decades (35, 36). 
In a report released in 2014, the World Health Organization (WHO) warned 
that antibacterial resistance (ABR) within a wide range of infectious agents has 
become a growing public health threat (37). Furthernore, the WHO announced 
that we have entered a “post-antibiotic era” in which infections caused by 
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bacteria, parasites, viruses, and fungi can no longer be treated (37).  
Aimed at defeating the drug-resistance threat, numerous efforts have been 
taken to find novel antibiotics, and most of the work can be divided into two 
directions. The first direction is developing derivatives of existing potent 
antibiotics in a given class (36, 38). This strategy offers a safety margin since 
the structural core of the developed small molecule is known to be active; 
however, it also carries the risk that a resistance mechanism already exists (36, 
38). The other direction is finding novel targets, possibly with no cross 
resistance, and further using these targets in future rational drug design. Even 
though this latter strategy has elements of uncertainty, it still presents great 
potential for successful outcomes. 
As mentioned in the previous section, the ribosome is not only a validated 
target for small-molecule ligands in the anticancer field, but also one of the 
main antibiotic targets in bacteria. The bacterial ribosome is composed of three 
rRNAs (16S, 23S, and 5S) and about 54 ribosomal proteins (5). Despite its 
large size, only a few sites on the ribosome are targeted by currently marketed 
antibiotics,as revealed by biochemical studies and crystal structures (Tables 
1.1 and 1.2; Figures 1.4 and 1.5) (39). The 30S-targeting antibiotics bind near 
the P site and interfere with the initiation step of translation by preventing 
interactions between the initiator tRNA and the start codon (Table 1.1 and 
Figure 1.4) (39). The other 30S-targeting antibiotics bind mainly to locations 
around the A site to inhibit either tRNA delivery or mRNA-tRNA translocation 
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(Table 1.1 and Figure 1.4) (39). The peptidyl-transferase center (PTC) is 
where the binding sites for most of the 50S-targeting antibiotics are located 
(Table 1.2 and Figure 1.5) (39-41). There are a few exceptions, such as the 
orthosomycins, which interact with 23S rRNA H89 and H91, and the 
thiopeptides, which bind to H43 and H44 also in the 23S rRNA (39-41).  
 
Table 1.1. Binding sites, mechanisms of action, and target-related resistance 
mechanisms of selected 30S ribosome-targeting antibiotics.  
Antibiotic Binding 
site 
Inhibition 
mechanism 
Resistance mechanism References 
edeine P site initiation target modification (42)  
neomycin helix 44 translocation 
target modification, target 
mutation 
(43, 44) 
paromomycin A site translocation 
target modification, target 
mutation 
(45-47) 
spectinomycin helix 34 translocation 
target modification, target 
mutation 
(48-50) 
streptomycin A site translocation 
target modification, target 
mutation 
(48, 51) 
thermorubin helix 44 initiation not determined (52, 53) 
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Table 1.2. Binding sites, mechanisms of action, and target-related resistance 
mechanisms of selected 50S ribosome-targeting antibiotics.  
Antibiotic 
Binding 
site 
Inhibition 
mechanism 
Resistance 
mechanism 
References 
chloramphenicol A site 
peptide bond 
formation 
target modification, 
target mutation 
(54-61) 
clindamycin, 
lincomycin 
peptide exit 
tunnel 
peptide bond 
formation 
target modification, 
target mutation 
(54, 57, 60, 62, 
63) 
erythromycin 
peptide exit 
tunnel 
nascent chain 
elongation 
target modification, 
target mutation 
(55, 57, 59, 62, 
64, 65) 
linezolid A site 
peptide bond 
formation 
target modification, 
target mutation 
(66-71) 
neomycin helix 69 translocation 
target modification, 
target mutation 
(43, 44) 
puromycin A site 
peptide bond 
formation 
no target-related 
mechanism detected 
(72) 
sparsomycin A site 
peptide bond 
formation 
target modification (55, 72, 73) 
thermorubin helix 69 initiation not determined (52, 53) 
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Figure 1.4. Overview is given of the binding sites of selected 30S ribosome-targeting 
antibiotics on the 30S subunit ribosome, including spectinomycin (green), 
paromomycin (red), streptomycin (blue) (PDB: 1FJG), neomycin (magenta, PDB: 
4GAQ/R/S/U) and edeine (yellow, PDB: 1I95). The h44 region is highlighted in pink for 
reference.  
 
 
 
 Figure 1.5. Overview is given of the binding sites of selected 50S ribosome
antibiotics on the 50S subunit ribosome with H69 highlighted in pink for reference. Top: 
sparsomycin (red, PDB: 1M90), macrolides (green, PDB: 1K9M), puromycin (blue, PDB: 
1Q82), and neomycin (magenta, PDB: 4GAQ/R/S/U) are shown. Bottom:  
chloramphenical (red, PDB: 3OFA
erythromycin (blue, PDB: 3OFO
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-D), clindamycin (green, PDB: 3OFX
-R) are shown. 
 
 
-targeting 
-0), and 
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Although resistance mechanisms have already been observed in some of 
the ribosome-targeting antibiotics, most of them have arisen from target 
alteration via modification or target mutation (47-78). There is still great 
potential in finding novel targeting sites in the structurally diverse yet 
sequence-conserved portions of the ribosome. With respect to finding possible 
novel drug-binding sites, chemical probes are needed to examine the 
structural details of rRNA both in vivo and in vitro. Similarly, investigating how 
small charged molecules interact with the ribosome will also be important for 
providing insight into future drug design. 
 
1.3 Introduction to cisplatin  
1.3.1 The discovery of cisplatin 
As an inorganic metal complex, cisplatin was first synthesized in 1844 by 
Michel Peyrone (74). More than one hundred years later (1966), an X-ray 
crystal structure of cisplatin was published, confirming its cis configuration (75). 
Not long after that, Barnett Rosenberg observed the curious phenomenon that 
cell division ceased and cell morphology dramatically changed during an 
investigation of electric field effects on bacterial cell growth (74, 76). He later 
discovered that this effect was caused by a Pt-based compound generated 
from the platinum electrode and buffer (74, 76). This work led to the discovery 
of the antitumor activity of cisplatin (74, 76). In 1969, Rosenberg and his 
coworkers published an article entitiled "Platinum compounds: a new class of 
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potent antitumor agents" in the journal Nature (77). After further evaluation, 
cisplatin was successfully pushed through clinical trials and was approved by 
the Food and Drug Administration (FDA) in 1978 as the first platinum-based 
anticancer drug (74). This officially started the era of platinum anticancer drug 
discovery with cisplatin taking the lead. 
 
1.3.2 The structural components of cisplatin 
Cisplatin is well known as a square-planar compound with a platinum 
metal center (Figure 1.6). As a third row transition metal, Pt has two dominant 
valence states, +2 and +4, and, in cisplatin, its charge is +2. Platinum(II) has a 
dsp2 hybridization state on its first four empty d orbitals and a square-planar 
configuration. Two groups of ligands are attached to Pt: two chlorido ligands, 
each with a -1 valence state, that coordinate to Pt in a cis fashion, and two 
neutral ammine ligands. Based on the hard-soft acid-base (HSAB) principle, 
Pt(II) is a relatively soft acid that can coordinate with soft bases (78). The Cl- 
ligand is a harder base compared to NH3, which makes its coordination to Pt(II) 
relatively weaker. Prior to the action of cisplatin against its cellular targets (this 
will be discussed in detail in the following sections), the Cl- ligand must 
dissociate from Pt and is therefore referred to as the "leaving group" or "labile 
ligand" (74, 76). On the other hand, ammine-ligand coordination with Pt(II) is 
more thermodynamically stable, so NH3 is referred to as a "non-leaving group" 
or "carrier ligand" (74, 76). Each ligand has its role in determining cisplatin's 
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reactivity and mechanism of action. The cis configuration is also critical to its 
anticancer activity (79, 80). During the discovery of cisplatin activity, its trans 
isomer, transplatin, was also synthesized and tested for antitumor activity; 
however, no comparably useful pharmacological effects were exhibited 
(Figure 1.6) (79, 80).  
 
 
Figure 1.6. The chemical structures of cisplatin and transplatin are shown (74, 76).  
 
1.3.3 Pharmacological mechanism of cisplatin 
Cisplatin demonstrates great efficacy in a variety of solid tumors, with over 
90% cure rates in testicular and ovarian cancer when tumors are discovered 
early (74, 81). The biological mechanism behind its antitumor activity has been 
thoroughly investigated since its serendipitous discovery. It is widely accepted 
that DNA is the main target (74). This section will focus on the cellular 
processes that lead to the formation of cisplatin-DNA adducts and the 
subsequent cellular responses, which eventually induce cancer cell death. 
The first question that needed to be answered in this field was, how does 
cisplatin enter the cancer cell? Although the biological mechanism of cell entry 
is not fully understood, it is believed that passive diffusion is a main contributor 
(82). After intravenous administration to a cancer patient, cisplatin rapidly 
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diffuses into tissues. The chloride concentration in blood serum is around 100 
mM; therefore, the aquation of cisplatin is inhibited and the compound remains 
in its neutral form when it reaches the outer membrane of the cancer cell 
(83-86). After cisplatin diffuses through the lipid bilayer, it faces the cellular 
environment, which has a much lower chloride concentration (around 4-12 mM) 
(81, 87). This environment facilitates aquation of cisplatin to its cationic forms, 
[PtCl(H2O)(NH3)2]+ and [Pt(H2O)2(NH3)2]2+. Cationic molecules with no 
hydrocarbon components are rarely able to diffuse through the biological 
membranes of higher organisms; therefore, mono- and bis-aquated cisplatin 
cannot diffuse back out of the cell, which results in its intracellular 
accumulation (Figure 1.7) (83-86).     
  Other than passive diffusion, some facilitated or active transport 
mechanisms may also contribute to cisplatin cellular uptake (Figure 1.7) (88). 
The connection between a copper transporter and cisplatin uptake has been 
observed in some transposon mutagenesis experiments (89, 90). Cells lacking 
copper uptake protein Ctr1 displayed increased resistance to cisplatin and 
analogues; whereas, overexpression of Ctr1 led to greater cisplatin 
intracellular accumulation (89-91). Some organic cation transporters (OCT) 
were also associated with cisplatin uptake (92).  
Once inside the cell, cisplatin is activated by aquation (Figure 1.7). The 
mono- and bis-aqua cations are reactive towards various biomolecules with 
nucleophilic centers, including DNA, since H2O is a better leaving group than  
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Figure 1.7. A schematic representation of the in vivo reactivity and aquation chemistry 
of cisplatin and the obstacles that the drug finds before reaching nuclear DNA is 
shown. 
Cl- (93). Before aquated cisplatin can reach the DNA in the nucleus, it can 
coordinate to many cellular constituents such as thiol-containing proteins, 
S-donor ligands, and RNA (93). It is estimated that less than 1% of cellular 
accumulated cisplatin actually ends up binding to nuclear DNA (Figure 1.7) 
(94). This non-specific targeting of cisplatin to cytoplasmic components may 
contribute to its mechanism of cytotoxicity.  
As mentioned previously, after 40 years of research, evidence has 
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accumulated that indicates the nuclear DNA as the major biological target of 
cisplatin (88). Once it enters the nucleus, because of the high concentration 
and the nucleophilicity of the nucleotides, cisplatin will react primarily with DNA 
(88). The aquated cisplatin derivatives, [PtCl(H2O)(NH3)2]+ or 
[Pt(H2O)2(NH3)2]2+, readily modify DNA at the N7 positions of deoxyguanosine 
and deoxyadenosine to form monofunctional or bifunctional adducts (88, 95). 
The metal binding reaction occurs mainly in the DNA major groove due to the 
higher accessibility compared to the minor groove (88, 95).   
Research done using DNA repair-deficient cells has provided convincing 
evidence that DNA platination is responsible for cisplatin's anticancer activity 
(96, 97). As shown in Figure 1.8, the reaction of cisplatin with DNA leads to the 
formation of various structural adducts. First, monofunctional adducts are 
formed, then most of them further react with a second nucleotide to produce 
inter- or intrastrand cross-links (98, 99). Among all of the known DNA-cisplatin 
adducts, at least 95% are intrastrand cross-links with 65% 1,2-d(GpG), 25% 
1,2-d(ApG), and 5-10% 1,3-d(GpNpG) adducts (100). Minor adducts are also 
present in a small percentage, including monofunctional adducts, DNA-DNA 
interstrand cross-links and DNA-protein cross-links (81, 87, 88). Cisplatin 
almost exclusively coordinates to the N7 position of purine bases, with 
preference for deoxyguanosine (101).  
Among the various platinum-DNA adducts, intrastrand cross-links have 
been the focal point of interest. Formation of cisplatin adducts, especially 
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Figure 1.8. The types of cisplatin-DNA cross-links and their corresponding ratios are 
shown. The platinum atom of cisplatin coordinates to the N7 position of purines, with 
preference to deoxyguanosine over deoxyadenosine, to form 1,2- or 1,3-intrastrand 
cross-links, interstrand cross-links, and monofunctional adducts.  
intrastrand cross-links, significantly alters the DNA structure and destabilizes 
the DNA by unwinding and bending the duplex (102, 103). The trans isomer of 
cisplatin, trans-DDP or transplatin (Figure 1.6), is a clinically ineffective 
compound. Due to steric reasons, it is unable to form intrastrandnadducts, 
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especially 1,2-intrastrand cross-links (87). The major cisplatin adduct, the 
1,2-intrastrand cross-link, bend the duplex toward the major groove and leave 
a widened and shallow minor groove to which several classes of proteins bind 
(Figure 1.9A). In contrast, interstand cross-links bend the duplex toward the 
minor groove (Figure 1.9C) (104, 105). The structural details of 1,2- and 1,3- 
intrastrand and interstrand cross-link platinum-DNA adducts are illustrated in 
Figure 1.9 (104-106).  
The presence of a kinetically inert bond between platinum and DNA can 
lead to several consequences, such as inhibiting the ability of DNA to function 
in replication and transcription (81). These effects then trigger subsequent 
cellular responses such as cell-cycle arrest and DNA repair (107).  
Cisplatin can induce not just apoptosis, but also the necrosis (Figure 1.10) 
(108, 109). Apoptosis and necrosis are different in both morphology and 
mechanism (110, 111). Apoptosis, or programmed cell death, generally results 
from the activation of the caspase family of aspartate-specific proteases and 
occurs as a defense mechanism (110, 111). It is also the main response of 
cells to chemotherapeutic agents such as cisplatin (107). Necrosis is 
traditionally defined as an accidental cell death caused by traumatic damage 
(110, 111). It is often characterized by cytosolic swelling and early loss of 
plasma-membrane integrity (110, 111). The mode of cell death induced by 
cisplatin is concentration dependent (108). Excessive cisplatin-induced DNA 
damage has been shown to hyper-activate the poly(ADP-ribose) polymerase 
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(PARP),
 
Figure 1.9. The crystal structures of three platinum-DNA adducts are shown. Cisplatin  
A) 1,2-d(GpG) intrastrand (PDB: 1A84), B) 1,3-d(GpTpG) intrastrand (1DA4), and C) 
interstrand cross-link (1A2E) structures were generated with Pymol. In the left panel, 
deoxyguanosine residues are indicated in green, with deoxyadenosines in blue, 
deoxycytidine in yellow and deoxythymine in magenta; in the right panel, two strands of 
DNA are marked separately in deep teal and pale green. Cisplatin is indicated in red. 
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which cleaves the glycolytic coenzyme NAD+ and provokes the formation of 
poly(ADP-ribose) moieties, thereby causing NAD+/ATP depletion, resulting in 
necrosis (Figure 1.10) (112).  
 
Figure 1.10. Cisplatin-induced DNA damage triggers two different modes of cell death, 
apoptosis and necrosis (TCR is transcription-coupled repair.) (104-109). 
 
1.3.4 Cisplatin and RNA 
As an important part of the translation process and a modulator of gene 
expression, RNA has critical and essential roles in the life cycle of cells. As a 
result, targeting RNA has peaked the interest of scientists as a promising 
direction in drug discovery and development. Cisplatin is known to form 
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exchange-inert complexes with DNA, and its antitumor activity is believed to 
result from its ability to cause DNA damage (81, 88). As mentioned previously, 
it is well established that before cisplatin enters the nucleus, most of the 
activated complexes (mono- or bis-aquated species) bind to cytoplasmic 
components, such as RNA, and possibly contribute to cytotoxicity (91, 92). 
Similar to DNA, RNA is also abundant in nucleophilic nucleotides. As roughly 
estimated in reported molecular biology experiments, there are approximately 
6 picograms of DNA and 32 picograms of RNA in a mammalian cell (113, 114). 
However, compared to DNA, there have been limited studies on the 
interactions between RNA and Pt(II)-based compounds.  
In the last ten years, there were a growing number of reports on 
cisplatin-RNA interactions, which helped to provide evidence that Pt(II) 
coordination to cellular RNA may potentiate the established DNA-based 
mechanism of cisplatin (115-122). A number of recent studies have 
characterized cisplatin reactivity with isolated RNAs by using radioactive 
labeling and enzymatic footprinting (115-122). The types of RNAs in these 
reports varied, and the sizes ranged from small interfering RNA (~20 
nucleotides) to the whole bacterial ribosomal RNA (~4500 nucleotides) (Figure 
1.11) (115-122). A biochemical study conducted by Hägerlöf and coworkers 
focused on comparing the reactivity of two RNA and DNA hairpins, namely 
r(CGCGUUGUUCGCG) and d(CGCGTTGTTCGCG), towards cisplatin and its 
derivatives (115). The results indicated that similar to DNA, cisplatin tends to 
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Figure 1.11. The sequence and secondary structures of RNAs in which the coordination 
sites of cisplatin have been mapped and identified are summarized. The RNA structures 
that have been studied include A) tRNAAla (left) and truncated models of its acceptor 
stem (middle, sMhAla) and anticondon loop (right, acMhAla) (117), B) an RNA hairpin 
(RNAI) (115), C) a purine-rich internal loop derived from the spliceosome (BBD) (118), 
and D) helix 24 of the small subunit ribosomal RNA in E. coli. (119). The binding sites 
identified in these RNAs are indicated by stars or labeled with Pt in red. 
coordinate with G residues in RNA, and binding to RNA was kinetically 
preferred over DNA (Figure 1.11B) (115). Furthermore, the Elmroth group 
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employed full-length tRNAAla as well as hairpin models of its acceptor stem and 
anticodon loop in cisplatin reactions, to closely analyze cisplatin's binding 
preferences to RNA secondary structures (for examples of RNA secondary 
structure types, see Figure 1.12) (116, 117). Combined, these data showed 
that coordination of cisplatin to RNA is highly sequence and structure 
dependent with a common preference for G-C-rich single-stranded regions 
(Figure 1.11A) (116, 117). 
 
Figure 1.12. Schematic representation of RNA secondary structures is given. 
Early studies on cisplatin-treated cells or cell extracts showed that cisplatin 
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is able to inhibit important RNA-related processes such as translation and 
splicing (123-125). These processes depend heavily on RNA structure and are 
mediated by RNA-RNA and RNA-protein interactions (123-125). This finding 
was later supported by the discovery of cisplatin coordination to tRNA and 
cross-linking to the internal loop of spliceosomal RNAs (Figure 1.11A and C) 
(117, 118). DNA-cisplatin interactions and adduct distribution are now well 
understood. In contrast, little is known about the number or distribution of 
RNA-Pt adducts. In a recent report conducted by DeRose and coworkers, 
RNA-Pt adducts from cisplatin-treated Saccharomyces cerevisiae were 
quantified (121). The in-cell Pt concentration and Pt accumulation levels were 
measured by using inductively coupled plasma mass spectrometry (ICP-MS) 
(121). The results revealed that, compared to DNA, cisplatin can accumulate 
faster and be retained on RNA, especially rRNA (121). This work suggested 
that rRNA can be a target candidate for Pt(II)-based drugs. It was also pointed 
out that a single [Pt(NH3)2] adduct on an RNA strand is enough to interfere with 
several enzymatic activities, including exonuclease, endonuclease, and 
reverse transcriptase (120).  
Platinum modification is capable of disrupting the native RNA structure, 
causing possible alterations in RNA tertiary structure and enhancing 
cytotoxicity in vivo. Comprehensive analysis by our laboratory has 
documented cisplatin coordination within the translation machinery (119). 
Stable platinum adducts have been mapped to various locations within E. coli 
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rRNA through primer extension and enzymatic digestion of platinated rRNA 
(Figure 1.11D). Based on previous findings, we were prompted to carry out 
further studies, especially with rRNA, to explore novel targets for Pt(II)-based 
drugs.  
   
1.3.5 Cisplatin as a chemical probe 
As mentioned in Section 1.2, ribosomal RNA is a validated target for both 
anticancer and antibacterial drugs, and it still has great potential for further 
exploration. In the interest of finding possible target sites, selective chemical 
reagents are needed to probe the structural details of rRNA in vivo and in vitro. 
Several chemical probes (Figure 1.13) have been commonly used in RNA 
structure studies, such as dimethyl sulfate (DMS) and 2'-hydroxyl acylation 
analyzed by primer extension (SHAPE) (126-130). Chemical probing has been 
revealed as a great approach to determine the reactivity of individual 
nucleotides under near physiological conditions or at different pH or salt 
concentrations. Compared to crystallography and NMR methods, chemical 
probing is convenient and has a low requirement for sample quantity and 
homogeneity. This further allows its application in monitoring the effects of 
various solution conditions on RNA conformations. Despite these advantages, 
chemical probes still have limitations. Most have poor cell membrane 
permeability and are not suitable for in vivo experiments. A few exceptions do 
exit, such as DMS and Pb2+ (128, 129). The mechanisms of the chemical  
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Figure 1.13. The target sites (A) and representative chemical probes (B) are shown. 
Underlining shows chemical probing detected after RNA strand scission by aniline 
treatment, whereas others are detected by direct reverse transcription analysis 
(128-131).  
probes rely on their reactivity with RNA and their product stability, such that the 
newly produced chemical adducts can be detected later with analytical 
methods (128). For example, DMS has been used for probing a variety of 
RNAs in vivo (128, 130, 131). It has the major experimental convenience that it 
can rapidly penetrate the cell and react with RNA without the need for harsh 
solution conditions (128, 130, 131). It reacts mainly with adenosine N1 and 
cytidine N3 (128, 130, 131). DMS can also react with guanosine N7; however, 
since the guanosine N7 is not involved in Watson-Crick base pairing, 
methylation at this site does not inhibit reverse transcription, making it difficult 
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to detect through standard biochemical procedures. Aniline treatment is 
needed to induce RNA strand scission at these sites before detection (Figure 
1.13) (128, 130, 131).  
Enzymatic probing is another method commonly used for RNA structure 
studies. Each enzyme has unique specificity to cleave RNA in a 
structure-dependent or sequence-dependent manner (132). For example, 
RNase A cleaves RNA single-stranded regions with UpN and CpN sequences, 
and RNase T1 reacts on the 3' side of guanosine residues (131, 133). RNase 
V1 is a double-strand-specific enzyme with no sequence preference (131, 133). 
Enzymatic probing can detect binding sites of small molecules that could 
cause severe steric hinderance or conformational changes that inhibit RNase 
activity. Due to the size of these enzymes and their inability to enter the cell 
easily, enzymatic probing is limited to in vitro studies.   
The use of cisplatin as a probe of RNA was reported by a previous lab 
member, Dr. Keshab Rijal. His study focused on Pt(II) complexes, especially 
cisplatin, as chemical probes for identifying solvent-accessible nucleotides in 
intact bacterial ribosomes in vivo and in vitro (119, 122). Cisplatin forms stable 
and inert bonds with RNA, which allows the platinated rRNA to be extracted 
and analyzed (119, 122). The rRNA platination sites are identified as "stops" by 
radioactive labeling with a primer extension reaction (119, 122). His results not 
only provided valuable information on rRNA structural accessibility to charged 
small molecules, but also showed RNA-cisplatin interactions in vivo. 
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Platinum-based compounds as chemical probes have specific advantages 
such as 1) efficient cell membrane permeability, and 2) easy quenching of the 
cisplatin reactivity in high chloride concentrations. Another key advantage of 
platinum-based probes is the ease with which their properties such as size and 
charge can be altered. Due to cisplatin's preferred reactivity, the structural 
information obtained has been limited to G-rich regions. In order to vary the 
potential coordination sites and gain further information about accessibility of 
rRNA towards various ligands, platinum(II) complexes were modified to 
achieve altered reactivity.   
 
1.3.6 Cisplatin derivatives 
Cisplatin, as the first FDA-approved Pt(II)-based anticancer drug, has 
been presented as belonging to a unique class of antitumor agents. During 
early clinical trials, it was soon realized that cisplatin's toxic side effects hinder 
its wide application (134-136). In addition, the emergence of drug-resistant 
tumor cells has further limited the overall efficiency of cisplatin (137, 138). 
Cisplatin's success and limitations prompted a parallel synthetic effort to 
design more effective and less toxic as well as orally available platinum 
analogues (139).  
As discussed in Section 1.3.2, cisplatin has several major structural 
components that are critical for its reactivity, such as leaving groups (chlorido), 
non-leaving groups (ammine) and cis configuration. These structural features 
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can be strategically modified in designing new platinum anticancer agents. 
Since cisplatin is administered as a relatively unreactive complex, its 
anticancer mechanism requires aquation of the chlorido ligands to yield 
monoaquated and bisaquated complexes (140, 141). The rate-determining 
step for cisplatin's initial binding to DNA is hydrolysis of the first chlorido ligand 
via association of solvent water (Figure 1.14) (140, 141). Complexes that react 
quickly are generally more toxic because of indiscriminate binding to off-target 
biological molecules. It has been hypothesized that modification of cisplatin 
with less labile leaving groups will reduce or alter its toxicity.  
 
Figure 1.14. Ligand exchange equilibria for cisplatin with values taken from the 
literature (140, 141) are shown. 
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In the search for a less toxic agent, carboplatin was designed and 
synthesized at the Institute for Cancer Research in the U.K. (Figure 1.15)  
(142). Compared to cisplatin, the leaving groups in carboplatin are replaced by 
a cyclobutanedicarboxylate (CBDCA) ligand, which is a relatively strong 
chelator to Pt(II). Using a murine screen for nephrotoxicity, carboplatin does 
indeed demonstrate diminished renal effects and retains antitumor activity 
(143, 144). As a result of its lower toxicity profile, carboplatin is able to be 
administered at higher doses (145-148). However, since the activated form 
(bisaquated) of carboplatin and cisplatin are still the same, they exhibit similar 
spectra of activity and cross-resistance (145-149). Carboplatin demonstrates 
that modifications on the leaving ligands can result in different toxicity profiles, 
indicating that the non-leaving group determines the adduct structures. It has 
also been hypothesized that modifications on the non-leaving group could 
affect the profile of the resulting Pt(II) adducts and further influence the cellular 
repair pathway responses to those adducts (150-152). With the above 
understanding and goals, oxaliplatin was developed by substituting the 
ammine ligands of cisplatin with 1,2-diaminocyclohexane and the chlorido 
ligands with oxalate group (153-156). With different carrier (non-leaving) 
ligands, oxaliplatin possesses a different spectrum of activity and displays no 
cross-resistance with cisplatin or carboplatin (Figure 1.15) (150, 151, 157). 
Over one thousand complexes have been synthesized and tested for better 
anticancer profiles than cisplatin. Only carboplatin and oxaplatin have been 
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approved by the FDA for clinical use worldwide (158-160).  
 
 
Figure 1.15. The chemical structures of the FDA-approved cisplatin-derivative 
anticancer drugs are shown. Red-dashed boxes indicate the non-leaving group/carrier 
ligands, and the blue-dashed boxes indicate the leaving group/labile ligands.  
 
1.4 Objectives of this project 
The rRNA binding sites for currently available ribosome-targeting 
antibiotics and potential anticancer drugs are limited to a relatively small region  
of the entire ribonuclear complex. The ribosome still has great potential to 
provide novel sites for new drug discovery in the cancer field. At the same time, 
increasing antibiotic resistance also necessitates the search for new bacterial 
target sites and novel drug design. Cisplatin as an active metal compound can 
form stable products with RNA, which are detectable by analytical methods. 
Probing structured RNA with cisplatin can provide information about potential 
“druggable” sites on RNA, but the reactive sites are mostly limited to 
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accessible guanosine sites. Modified cisplatin analogues with altered 
functionality are needed to obtain a more comprehensive understanding of the 
rRNA structural details as well as RNA's overall interactions with different sized 
and charged compounds. In addition, it was reported recently that besides 
targeting DNA, cisplatin can accumulate faster and be retained on RNA, likely 
causing damage to the RNA structure and potentiating its established 
DNA-based mechanism (118, 120, 121). These results promote the 
development of RNA-targeting Pt compounds as a promising direction to 
overcome DNA repair-related resistance and to reduce dose-related side 
effects. For the dual purpose of developing both RNA-targeting chemical 
probes and anticancer drugs, understanding the structure-activity relationships 
between RNA and Pt compounds is especially important.  
The objectives of my Ph.D. work are to: 1) develop cisplatin analogues to 
achieve altered reactivity from the parent compound, 2) use model systems to 
characterize the product profiles and kinetics of cisplatin derivatives, 3) obtain 
information on how ligands alter the Pt(II)-RNA interaction by comparing 
analogue structure and reactivity with cisplatin, and 4) develop new 
methodologies to further investigate the platination effects on chemical stability 
of RNA as well as explore the potential of Pt(II) complexes to be RNA-targeting 
anticancer drugs.  
The information obtained by using the approaches described above can 
help enrich our understanding of the structure-activity relationships (SAR) 
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between Pt(II) complexes and RNA, and further benefit the future development 
of both RNA-targeting chemical probes and anticancer drugs (Figure 1.16). 
 
 
Figure 1.16. The project overview is shown (PDB: 2I2T, 2I2P). 
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CHAPTER 2  
Synthesis and characterization of amino-acid-linked cisplatin 
analogues 
2.1 Abstract  
In the last few decades, thousands of platinum-based complexes have 
been synthesized and screened for potential biological activity, but only a few 
were successful. Based on previous analogue studies, we hypothesize that 
modification of cisplatin can lead to compounds that have the potential to 
produce different platination profiles than the parent compound. In this chapter, 
amino acids were employed as ligands to obtain platinum(II) compounds with 
different sizes and charge distributions. The products were then characterized 
by NMR spectroscopy, infrared spectroscopy, and mass spectrometry to verify 
their chemical compositions and structures before testing them in subsequent 
reactions with RNA. 
 
2.2 Introduction  
Cisplatin was the first FDA-approved platinum anticancer drug. Its 
pharmacological mechanism has been studied in detail, as summarized in the 
previous chapter. Treatment with cisplatin is limited by severe side effects, 
including nephrotoxicity, neurotoxicity, and emetogenesis, as well as 
increasing resistance that is related to systematic DNA repair (161). In order to 
overcome these limitations, thousands of cisplatin analogues have been 
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synthesized (74, 162). Among all of the studied analogues, amino-acid-linked 
platinum compounds have drawn the most attention for our work.  
An amino acid (aa) is the monomer unit of a protein; it has the general 
structure of one carboxylate group, one amino group, and a side chain 
connected to a chiral carbon (except glycine). With different side chains 
properties, amino acids can be divided into four groups: 1) acidic amino acids, 
such as aspartic acid (Asp, D) and glutamic acid (Glu, E); 2) basic amino acids, 
like lysine (Lys, K), arginine (Arg, R), and histidine (His, H); 3) hydrophobic 
ones, with alanine (Ala, A), leucine (Leu, L) and phenylalanine (Phe, F) as 
examples; and 4) polar amino acids, such as methionine (Met, M) and cysteine 
(Cys, C) (163). There are 22 common amino acids that are naturally abundant, 
and even more non-standard amino acids occur in biology due to 
post-translational modifications (163). They also serve as metabolic 
intermediates. With their great variety and abundance, amino acids comprise a 
convenient ligand pool for platinum-amino acid chemistry studies.  
Platinum(II) is a relatively soft metal center. Amino acids could coordinate 
to platinum through nitrogen, oxygen, or sulfur donors. There is also the 
possibility for a single amino acid to coordinate to Pt(II) in a monodentate, 
bidentate, or tridentate fashion. In addition, the binding of more than one 
amino acid to a single platinum center is possible. All of the potential binding 
modes and the possible formation of geometric isomers contribute to the 
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molecular diversity of platinum-amino acid compound libraries, which makes 
them ideal candidates for studying ligand effects on RNA-Pt(II) reactivity.  
There have only been a few reports on platinum-amino acid compounds 
and their properties. In 1994, Lorraine Webster's group reported on an 
O-methyl-methionine-linked Pt(II) complex with methionine coordinating to Pt 
through sulfur and nitrogen (Figure 2.1A) (164).  
Figure 2.1. The chemical structures of six Pt-amino acid compounds are shown. A) Two 
methionine-linked Pt compounds are shown, one with a cis configuation (left) and the 
other with a trans configuration (right) (164, 165); B) two basic-amino-acid-linked 
cisplatin analogues are shown (166-168); C) two histidine-linked cisplatin analogues are 
shown (169, 170). The charges at pH 7.0 are indicated. 
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Subsequent cell studies showed no significant activity against leukemia 
(164). Almost 20 years later, a methionine-linked Pt(II) trans complex was 
reported with improved platination rates with DNA compared to the trans 
isomer of cisplatin (Figure 2.1A) (165).  
Janina Altman, Meir Wilcheck, Avi Bino, and coworkers published two 
articles in the 1980s on amino-acid-linked platinum compounds (166, 171). 
Lysine and ornithine were chosen as the ligands and the crystal structures 
were determined (Figure 2.1B) (166, 171). Both lysine and ornithine formed a 
1:1 Pt:aa bidentate complex through the α-amine and carboxylate group 
(referred to as Kplatin and Oplatin, respectively); however, their anticancer 
activity was not tested nor mentioned in these papers (166, 171). Later, two 
different groups (Lippard's group, in 1997 and Noto's group in 2006) both 
reported on the cytotoxicity of lysine- and ornithine-linked cisplatin analogues 
(167, 168).  
In an attempt to find cisplatin analogues with improved anticancer activities, 
Lippard's group screened amino-acid-linked Pt(II) complexes for cytotoxicity in 
a solid-phase assay by testing the binding of the corresponding DNA adducts 
to the high mobility group (HMG) domain protein (167, 172, 173). The HMG 
protein binds specifically to 1,2-intrastrand Pt(II) cross-linked DNA and further 
distorts the double-helical structure (174-177). HMG proteins can protect the 
cisplatin-induced DNA damage from repair, or be further hijacked by the 
platinum adducts from other essential cellular functions (174-177). The 
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screening results suggested the potential of the basic-amino-acid-linked Pt 
complexes (Figure 2.1) to be antitumor drug candidates. This activity was 
confirmed in toxicity assays (172, 178). Both Kplatin and Oplatin demonstrated 
comparable toxicity as cisplatin towards HeLa cells (172, 178).  
In 2006, Dalla Via et al. proposed a synthetic pathway for the 
ornithine-linked platinum complex, and solved its crystal structure (168). In the 
structure, it was revealed that the amino acid coordinates to the platinum 
center in a bidentate fashion, and Oplatin maintains a square-planar geometry 
similar to that of cisplatin (168). As reported in the above-mentioned literature, 
both Kplatin and Oplatin showed comparable antiproliferative activity to 
cisplatin (167, 168). These results further drew our attention and interest in 
evaluating their reactivity toward RNA and possibly developing them into 
RNA-targeting chemical probes or anticancer drugs.  
Amino acids have a common structure with one amine group and one 
carboxylic acid group, both of which can be electron donors and coordinate to 
Pt. As summarized above, many Pt(II) complexes with amino acids have a 
common structure, PtCl2(N,O-A) (where A is the amino acid) (164-169). A cis 
coordination has been observed with the amino and carboxylate groups 
forming a five-membered chelating ring with Pt (166, 171, 172, 179). However, 
the chelates of basic amino acids sometimes demonstrate other coordinating 
modes due to the nitrogen-containing side chains. Reports have suggested 
that histidine can bind to Pt through both the α-amine and the nitrogens of the 
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imidazole ring (Figure 2.1C) (160, 161). Similar to histidine, molecules such as 
ornithine may theoretically react through three possible pathways, leading to 
the formation of N,O-eight-membered (Figure 2.2, left), N,N-seven-membered 
(Figure 2.2, right), or N,O-five-membered (Figure 2.1B, left) using 
compounds. 
 
Figure 2.2. The possible chemical structures of the eight-membered (left) and 
seven-membered (right) cis-[PtCl2(Orn)] compounds are shown. The charges at pH 7.0 
are indicated. 
The overall goal of the work reported in this chapter was to optimize the 
synthetic scheme for the basic-amino-acid-linked Pt(II) complexes and to verify 
their chemical composition and structures (Figure 2.3). The work focused 
mainly on the ornithine and glycine complexes although lysine, histidine, and 
tyrosine were also examined as potential ligands. 
 
2.3 Materials and methods  
2.3.1 General 
Potassium tetrachloroplatinate (K2PtCl4) was purchased from Strem 
Chemicals, Inc. (Newburyport, MA). L-Ornithine hydrochloride, glycine, 
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aspartic acid and tyrosine were purchased from Alfa-Aesar (Ward Hill, MA). All 
other chemicals and reagents were purchased from Sigma (St. Louis, MO) or 
Fisher (New York, NY). RNase-free, distilled, deionized H2O (ddH2O) (Millipore, 
Billerica, MA) was used for all experiments. 
Figure 2.3. The chemical structures of four Pt-amino acid compounds synthesized are 
shown. The charges at pH 7.0 are indicated. 
 
2.3.2 Synthesis of glycine- and ornithine-linked cisplatin analogues 
Synthesis of cis-[PtCl2(N,O-Gly)](1) 
For the glycine-linked platinum complex (1), the general synthesis 
procedure was similar to a published synthetic procedure for Oplatin (2), but 
was altered and optimized to obtain the best yield of the 1:1 Pt:glycine product 
(168). Potassium tetrachloroplatinate (K2PtCl4) (0.070 g, 0.17 mmol) was 
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dissolved in 1 mL ddH2O and stirred at RT for at least 3 h until a red solution 
was obtained. Glycine (0.013 g, 0.17 mmole) was added to 1 mL ddH2O and 
vortexed until dissolved completely. The glycine and potassium 
tetrachloroplatinate solutions were then mixed in a 1:2 volume ratio (resulting 
in a 1:1 molar ratio) and incubated at 70 oC in the dark for 6 h before being 
dried under vacuum. The crude product was then washed three times with 90% 
ethanol and the remaining precipitate was dried again under vacuum (0.014 g, 
0.041 mmol, 24%). νmax/cm-1 (FT-IR, KBr pellet): 3235 (νaNH2), 3139 (νsNH2), 
1654 (νaCO2), 1580 (δNH2), 1419 (δCH2), 1362 (νsCO2) and 1315 (δCH2); m/z 
(ES-MS-) 338.9.0 [M]-; chemical formular (M): PtC2H4Cl2NO2. 
Synthesis of cis-[PtCl2(N,O-Orn)] (2) 
The synthesis pathway of the L-ornithine-linked platinum complex (2) is 
based on previously published literature (168). Potassium tetrachloroplatinate 
(K2PtCl4) (0.070 g, 0.17 mmol) was dissolved in 1 mL ddH2O and stirred at RT 
for at least 3 h until a red solution was obtained. L-Ornithine hydrochloride 
(0.058 g, 0.34 mmol) was dissolved in 1 mL ddH2O and stirred at RT until a 
clear solution was obtained. L-Ornithine and the potassium tetrachloroplatinate 
solutions were mixed in a 1:1 volume ratio and the mixture was heated at 50 
oC for 12 h in the dark with gentle shaking until the color of the solution 
became dark. Next, the reaction mixture was evaporated to dryness under 
vacuum. A yellow powder was obtained, which was washed thoroughly with 
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cold water and dried. Hot H2O was used to dissolve the powder and 
recrystallize the product. The crystal was vacuum dried in the dark for 3 days 
at room temperature (0.027 g, 0.068 mmol, 40%). νmax/cm-1 (FT-IR, KBr pellet): 
3196 (νsNH2), 1643 (νaCO2), 1381 (νsCO2), 1301 (νsCO), 1243 (δNH2), 1180, 
1087, 1035 (νCN), 959 (νC-C), 749 (δNH2) and 656 (δCO2); δ/ppm (1H-NMR, 
D2O, 400 MHz): 3.48 (1 H, dd, JAB=6 Hz, JAC=12 Hz, -CHCH2-), 2.89 (2 H, t, 
-CH2NH3), 1.84 and 1.69 (4 H, m, -CHCH2CH2-); m/z (ES-MS-) 395.98 [M-H]-. 
chemical formular (M): PtC5H12Cl2N2O2。 
Synthesis of cis-[PtCl2(N,O-Arg)] (3) and cis-[PtCl2(N,O-Tyr)] (4) 
Other amino-acid-linked platinum complexes were also synthesized. The 
synthesis schemes were altered and tuned differently to achieve the best 
purity and yield for each case. For example, in order to improve the solubility, 
KOH was added in the synthesis of a tyrosine-linked Pt(II) complex (Yplatin, 4). 
For the synthesis of the arginine-linked Pt(II) complex (Rplatin, 3), KCl was 
added to prevent the guanidinium group from coordination to a second Pt atom. 
However, the synthetic schemes of Yplatin and Rplatin still need to be further 
optimized, and this part of the project is being carried out by Bett Kimutai. 
 
2.3.3 Nuclear magnetic resonance (NMR) spectroscopy, infrared (IR) 
spectroscopy, and mass spectrometry (MS) 
NMR spectroscopy was carried out on a Mercury-400S spectrometer in 
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the Lumigen Instrument Center in the Chemistry Department. All samples were 
dissolved in 99.9% D2O, and the signal was locked using D2O. All J values are 
given in Hz. All chemical shift values are reported in ppm and referenced to the 
solvent peak. Infrared spectra were taken as KBr pellets on a Tensor 27 FT IR 
spectrophotometer with the range of 4000-600 cm-1 (Dr. Claudio N. Verani's 
Lab, Room 130, Chemistry). Mass spectra were obtained on a 7T Bruker 
SolariX FT-ICR mass spectrometer (Dr. Mary T. Rodgers' Lab, Room 10, 
Chemistry), and methanol was used as the carrier solvent. 
 
2.4 Results and discussion 
The L-ornithine-linked platinum complex (Oplatin, 2) was synthesized and 
purified based on Dalla Via's procedure (168). The reaction is shown in 
Scheme 1. (40% yield). IR, NMR, and MS were performed to confirm its 
structure. Synthesis from starting material K2PtCl4 produced the 
cis-PtCl2(N,O-Orn) product 2 in modest yields (40%). It is a one-step, one-pot 
reaction done in water. An excess of ornithine
 
was used to obtain the best yield. 
The purification step was optimized based on solubility differences between 
free ornithine and compound 2 since the latter has poor water solubility 
compared to ornithine. The IR and NMR results (discussed in the following 
sections) are consistent with the literature, suggesting the successful 
generation and isolation of compound 2 (166, 168). MS data further confirmed 
the chemical composition of 2. 
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Scheme 1: Synthesis of the ornithine-linked platinum complex (Oplatin, 2) 
 
Figure 2.4. The IR spectra of L-ornithine hydrochloride (upper) and 2 (lower) are shown 
(ν = stretching, δ = bending, ζ = torsion, a = asymmetric vibration mode, s = symmetric 
vibration mode). 
As mentioned in Section 2.2, ornithine theoretically can form three 
possible products, containing N,O-eight-membered (Figure 2.2, left), 
N,N-seven-membered (Figure 2.2, right), or N,O-five-membered (Figure 2.1B, 
left) rings (168); however, formation of the large ring compounds (Figure 2.2) 
is expected to be unfavorable. In the IR spectrum of free ligand, L-ornithine 
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(Figure 2.4), a band typical of zwitterionic amino acids was observed at 2078 
cm-1 (168). This peak was attributed to a combination of α–NH3+ antisymmetric 
bending and torsional oscillation signals. Also, a clear band for COO- 
antisymmetric bending was seen at 1632 cm-1. After the reaction to form 2, the 
zwitterionic amino acid band was no longer present in the spectrum, 
suggesting that the α-amino group is deprotonated and coordinated to Pt. The 
COO- signal of the product shifted from 1632 to 1643 cm-1, a change also 
attributed to coordination to Pt through the carboxylate group. The major 
changes in the zwitterionic amino acid band and COO- signal suggest that 
ornithine coordinates to Pt(II) through the α–NH2 and COO- groups, and this 
further suggests that the reaction product is the proposed compound 2. The 
presumed five-membered ring structure was expected to localize the electrons 
in the acidic oxygen of COO-, causing an increase in the bonding strength of 
the carboxylate group. Detailed assignments of the IR signals are summarized 
in Figure 2.4. 
The 1H-NMR spectra (Figure 2.5) of ornithine and 2 are consistent with the 
literature (168). After coordination, a clear peak shift was observed, mainly on 
the C1 proton (Δδ = δligand - δcomplex = 3.60 ppm - 3.47 ppm), which suggests 
that the C1 proton is located closest to the Pt center. These results further 
support the assignment of compound 2 as the five-membered ring structure.  
Electron localization effects caused by five-membered ring formation would be 
expected to cause the C1 proton to be more shielded than in the free amino 
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acid, causing an upfield shift. Minor chemical shift and peak shape changes 
were also observed for the C2 and C3 proton signals. The C4 proton was 
affected the least, consistent with a longer distance to the Pt center. 
 
Figure 2.5. The NMR spectra of L-ornithine hydrochloride (upper) and 2 (lower) in D2O 
are shown. 
In addition to IR and NMR spectroscopy, mass analysis was carried out. 
The ESI-MS spectrum of 2 (Figure 2.6) showed a strong, dominant peak with 
an m/Z (Z=-1) value of 396.0 and signature Pt isotope distribution, which is in 
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agreement with the calculated exact mass based on the proposed structure of 
2 ([m-H]-: calculated 396.0; observed 396.0). This result, combined with the IR 
and NMR data, supports the structure of 2, and is consistent with previously 
reported compounds and X-ray structures (166, 168). The product was 
therefore ready for further reactivity analysis.  
 
Figure 2.6. Mass analyses of 2 are provided. A) The ESI-MS of 2 in negative detection 
mode is shown; B) a close-up view of the 395.98 m/Z signal revealed the signature Pt 
isotope distribution (upper) and matched the simulated spectrum (lower). 
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Scheme 2: Synthesis of the glycine-linked platinum complex (Gplatin, 1) 
 
Other amino-acid-linked platinum complexes, such as Gplatin (1), were 
also characterized by FT-IR and MS to confirm their structures. The reaction 
for compound 1 is shown in Scheme 2.  
 
Figure 2.7. The IR spectra of glycine (upper) and 1 (lower) are shown (ν = stretching, δ = 
bending, ζ = torsion, a = asymmetric vibration mode, s = symmetric vibration mode). 
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In order to compare the reactivity of different amino-acid-linked platinum 
complexes with varying side chains, Gplatin was used as a control compound 
in this study because it has no functional group on the Cα position. As 
mentioned in Section 2.2.2, different reaction conditions were tested in the 
Gplatin (1) synthesis in order to obtain 1:1 Pt:glycine coordination. Compared 
to 2, a higher temperature and shorter reaction time was employed. Due to the 
competing reaction to form the 1:2 Pt:glycine complex, the overall yield was 
very modest (24%). The IR spectrum of the product, 1 (Figure 2.7), showed 
the same disappearance of the typical zwitterionic amino acid peak (2118 cm-1 
in glycine) as 2, which indicated coordination of the α-amine to the metal 
center. In the ligand spectrum (Figure 2.7), the band corresponding to 
antisymmetric stretching of the COO- group at 1612 cm-1 was observed, and 
shifted to 1654 cm-1 in the product spectrum. This result was suggestive of 
five-membered-ring formation through the α-amine and COO- group, which 
was similar to Oplatin (2). The MS data provided further evidence for the 
structure shown in Figure 2.3. The isotope distribution in electrospray MS 
(Figure 2.8) agreed well with the simulated spectrum. The characterization of 
1 was therefore in accordance with the proposed structure (Figure 2.3).  
Besides Gplatin (1) and Oplatin (2), arginine- (3) and tyrosine-linked (4) 
platinum complexes were also synthesized; however, the synthetic 
methodology for the tyrosine-linked platinum complex still needs further 
optimization. The need for optimized reaction conditions for each amino acid is 
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likely due to differences in solubility as well as reactivity. 
 
Figure 2.8. Mass analyses of 1 is given. A) The ESI-MS of 1 in negative mode is shown; 
B) a close-up view of the 338.93 m/z signal exhibited the signature Pt isotope 
distribution (upper) and matched with the simulated spectrum (lower). 
 
2.5 Conclusions 
The first goal of this project was to synthesize various amino-acid-linked 
cisplatin analogues to achieve altered reactivity. At this point, compounds 
Gplatin (1) and Oplatin (2) were synthesized successfully with modest yields 
and purities, and were ready for subsequent RNA-reactivity studies (Chapter 
3). The MS data for Oplatin (2) provided complementary information on the H 
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atom composition to the reported X-ray structure (168), and further confirmed 
the chemical composition. The 1:2 Pt:ornithine complex was not observed 
during synthesis and characterization. The preference for the 1:1 Pt:ornithine 
complex is believed to be attributed to bulkiness and positive charge of the 
basic side chain. In contrast to compound 2, the synthesis of compound 1 was 
first reported here and the generation of exclusively the 1:1 complex was much 
more challenging. Therefore the product yield of 1 was lower compared to 2. 
Despite these challenges, Gplatin (1) serves as a useful control compound in 
this project to compare the reactivity of different amino-acid-linked platinum 
complexes with varying side chains. 
As a hydrophilic and basic amino acid, ornithine can only provide partial 
information regarding the basic side-chain effects on platinum reactivity 
profiles. In order to fully understand the side-chain effect and expand the 
library of Pt(II)-based chemical probes, other closely related amino-acid-linked 
cisplatin analogues are needed for comparison. For example, an 
Nε-dimethylated ornithine platinum complex will give some idea about how 
bulky groups (or altering H-bond capabilities) influence compound reactivity 
compared to Oplatin (2) (this project is now being continued by Supuni Thalalla 
Gamage). Therefore, synthesis, purification, and characterization of different 
amino-acid-linked platinum complexes using this methodology will be further 
optimized to provide a more complete library in the future. 
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CHAPTER 3 
Binding studies of Oplatin and Gplatin with single RNA 
nucleosides 
3.1 Abstract  
The cisplatin anticancer mechanism is based on the ability of platinum(II)  
to coordinate to the N7 of purines in DNA. Recent studies showed that RNA 
can also be considered as a target; platinum accumulates 10- to 20-fold faster 
in RNA compared to DNA, and can form stable products with RNA. In this 
chapter, both qualitative and quantitative analysis methods were developed to 
study Pt complex reactions with different RNA nucleosides by using high 
performance liquid chromatography (HPLC). The reactivities of Gplatin and 
Oplatin with adenosine and guanosine were evaluated and compared with 
cisplatin using this method. The preliminary product profile of Oplatin with RNA 
nucleosides was also determined by liquid chromatography-mass 
spectrometry (LC-MS). 
  
3.2 Introduction  
Since the initial discovery of cisplatin's anticancer activity, its mechanism 
of toxicity has been well established and commonly believed to involve DNA 
coordination and formation of irreversible products (81, 180). Recently 
published work from our laboratory and others indicates that cisplatin has 
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comparable or even better reactivity towards RNA, raising the possibility of 
RNA as a secondary drug target (119, 121). Furthermore, utilizing cisplatin as 
a chemical probe provided valuable structural information for rRNA (122); 
however, this information was limited to G-rich regions due to cisplatin's 
preferred reactivity. Several amino-acid-linked cisplatin analogues were 
synthesized (Chapter 2) and their reactivity towards the helix 24 (h24) region 
of the small subunit rRNA (16S rRNA in bacteria) was monitored (122). The 
h24 region was shown previously to be a strong target site of cisplatin (119, 
181). Syntheses of Dplatin, Kplatin and Rplatin were done by K. Rijal (122). 
The results with amino-acid derivatives of cisplatin demonstrated that with a 
different distribution of positive charge compared to the parental compound 
cisplatin, as well as different sizes and hydrogen-bonding capabilities, altered 
reactivity occurred (122,181). Cisplatin preferred to react with consecutive Gs, 
as well as Gs in mismatched or loop regions of h24 (122, 181). In contrast, 
Dplatin (aspartic acid-linked cisplatin analogue) had no significant reactivity, 
and both Kplatin and Oplatin exhibited a sequence preference for A residues 
and a structural preference for single-stranded regions (122, 181). Only one 
coordination site was detected with Rplatin, which was a three-nucleotide 
bulge region (A780, A781 and A782, Figure 3.1) (122, 181).  
Among the above amino-acid-linked cisplatin analogues, Oplatin (2) has 
drawn the most attention and has potential as a dual structure- and 
sequence-specific RNA-targeting compound because of its distinct reactivity  
57 
 
 
 
Figure 3.1. Probing results with Pt(II)-based complexes on helix 24 (h24) of 16S rRNA 
are shown (K. Rijal) (119, 120, 122, 181). A) Autoradiogram of probing results with 
cisplatin is shown. B) Autoradiogram of probing result with four amino-acid-linked Pt(II) 
complexes is shown. C) The chemical structures of the amino-acid-linked complexes in 
monoaquated forms are given. D) The secondary structure map of 16S rRNA at h24 is 
shown. The reverse transcription stops used to identify platinum sites occur one 
nucleotide prior to the coordination site. Strong reactive sites with cisplatin (  ), Oplatin 
and Kplatin (  ), and Rplatin (  ) are indicated.  
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from cisplatin. Previous studies focused on identification of the platination 
sites by using methods such as radioactive labeling and enzymatic footprinting 
(117, 120, 121, 182); however, these techniques provide little information 
about how the ligands affect Pt(II) complex reactivity on RNA at the nucloeside 
level. With the unique reactivity of monoaquated Oplatin on full-length RNAs, 
evaluating its nucleoside reactivity will provide an improved understanding of 
its capability as a higher-order structure probe. In order to examine more 
closely the nucleoside preferences of the amino-acid-linked analogues, 
reactions between the monoaquated Pt(II) complexes and nucleosides were 
monitored by HPLC. 
 
3.3 Materials and methods  
3.3.1 General 
HPLC grade acetonitrile, ammonium acetate (NH4OAc), sodium chloride 
(NaCl), sodium dihydrogen phosphate (NaH2PO3), disodium hydrogen 
phosphate (Na2HPO3), silver nitrate (AgNO3), N,N-dimethyl formamide (DMF), 
adenosine (A), guanosine (G) and all the other chemicals and reagents were 
purchased from Sigma-Aldrich or Fisher, unless otherwise stated. RNase-free, 
distilled, deionized ddH2O (Millipore water) was used throughout the 
experiments. 
 
3.3.2 Ultraviolet (UV) spectroscopy 
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An Aviv 14DS UV-visible spectrometer in Dr. David Rueda's laboratory was 
used for all UV measurements. 
 
3.3.3 Single nucleosides  
Single RNA nucleosides, guanosine and adenosine (structures and 
numbering are shown in Figure 3.2) were dissolved in water at room 
temperature. The concentration of each solution was determined by UV-visible 
spectroscopy. The extinction coefficients used for the A, G, U, C nucleosides 
are shown in Table 3.1 (16).  
    
Figure 3.2. The chemical structures of adenosine, guanosine, cytidine, and uridine are 
shown. 
Table 3.1. Extinction coefficients for RNA nucleosides  
Nucleoside pH λmax (nm) εmax (1/mol-1cm-1) 
A 6 260 14,900 
G 6 253 13,600 
U 7 262 10,100 
C 7 271 9,100 
ref (16) 
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After the nucleoside stock solutions were made, pH 6 or 7 sodium 
phosphate buffer (100 mM) was used in the dilution step (Table 3.1). The 
difference in UV absorbance between phosphate buffer and water was less 
than 0.15%. Dilutions were carried out so that the UV readings were all in the 
range of 0.1 to 1 OD to ensure high sensitivity of the UV spectrometer (183). 
The dilution factors varied from 100 to 250. All of the samples were prepared 
freshly. Beer's Law (Equation 3.1) was used to determine the stock 
concentration. 
A DC=
lε
×
•
                         
Equation 3.1 
in which A is UV absorbance at λmax, D is the dilution factor, l is pathlength (1 
cm), and ε is the extinction coefficient at λmax. 
 
3.3.4 Monoaquation and bisaquation of Pt complex 
The Pt complex was converted to the monohydrated or bisaquated forms 
before reaction with the RNA nucleoside. The aquated forms were prepared by 
addition of one or two equivalents of AgNO3 to a DMF solution of 
amino-acid-linked Pt complex, respectively (the hydrolysis reaction equations 
are shown in Schemes 3.1 and 3.2). The reaction mixture was incubated at 
room temperature in the dark for 12 h with constant shaking, and then the 
white precipitate, AgCl, was removed by centrifugation at 12,000 RPM for 15 
min. The supernatant of the platinum-DMF mixture was transferred into a new 
microcentrifuge tube and stored at -20 °C up to one week. The concentration 
61 
 
 
of each stock solution was calculated based on the mass of Pt complex used. 
The approximate concentration of stock solution was 5-6 mM. 
Scheme 3.1: Preparation of monoaquated amino-acid-linked platinum analogues  
 
Scheme 3.2: Preparation of bisaquated amino-acid-linked platinum analogues  
 
 
3.3.5 Platination of RNA nucleosides 
All platination reactions were carried out in a 25 mM sodium phosphate 
buffer, pH 7.0, 5 mM sodium chloride at 37 °C in the dark. The nucleoside 
stock solutions were freshly prepared every time as described in Section 3.3.3. 
The monoaquated or bisaquated Pt complex stock (1a, 1b, 2a and 2b) was 
prepared as described in Section 3.3.4 and diluted as required just prior to use. 
The RNA nucleosides were incubated at 37 °C with aquated complex in 1:1 
(with 1 mM nucleoside concentration), 1:10 (with 0.1 mM nucleoside 
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concentration), and 1:50 (with 0.1 mM nucleoside concentration) ratios of Pt to 
nucleosides. For reactions with 1:10 and 1:50 nucleoside: Pt molar ratios, two 
repetitions were done (error was calculated and indicated in the graphs). All 
reaction mixtures were incubated at 37 °C in the dark up to 24 h. At each time 
point, 25 μL of sample was taken from the reaction mixture and 3 μL of 2 M 
NaCl was added into the sample to quench the activity of the Pt complex. 
Following each incubation, the samples were immediately frozen on dry ice 
and stored in -80 °C until further analysis. All samples were centrifuged at 
12,000 RPM for 10 minutes to remove any precipitates before injection onto 
the HPLC. 
 
3.3.6 High performance liquid chromatography (HPLC) 
Samples were analyzed with a Supelco Discovery C18 column (5 μm 
particle diameter; 4.6 mm i.d. × 250 mm, Sigma-Aldrich, St. Louis, MO, USA) 
on a Waters 600 LC with a 717 autosampler (Waters, Milford, MA, USA) and 
UV-detector set at 254 nm. Forty mM NH4OAc, pH 6.5, was used as the 
running buffer, and acetonitrile was used as the elution buffer. A 95% NH4OAc 
buffer in H2O, with 2% acetonitrile and 3% H2O, was used for column 
equilibration at the beginning of the applied program, and then an acetonitrile 
gradient was applied (2 to 40% over 40 min). The average column pressure 
within this program was around 2200 psi. The retention times of the 
nucleosides were confirmed by injection of known standards. The peaks were 
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quantified using Empower software (Empower Software Solutions, Inc.) with 
the baseline set to the baseline integration method (the integration begins 
when the UV reading first begins to rise above the baseline and ends when it 
returns to the baseline.).  
 
3.3.7 HPLC standard calibration 
Stock solutions of single nucleosides were prepared as described in 
Section 3.3.3. For each nucleoside, at least three parallel sets of injections 
were performed to obtain the standard curves. In each set, 11 samples with 
different concentrations (from 25 pmole at 1 μM to 5 nmole at 200 μM) were 
prepared, and 25 uL of the sample was injected onto the HPLC and analyzed 
as described in Section 3.3.6. Between every two injections, one blank 
injection (water only) was made. The mean peak area was used as parameter 
Y versus the actual injected amount X (in qmoles). The standard error was 
also calculated for each point. The calibration curves of adenosine (A) and 
guanosine (G) were repeated two times over a six-month time period (each 
time with three parrallel sample sets, and the repeats were made at least one 
month apart). 
 
3.3.8 HPLC analysis of digested products of 23S rRNA platination 
HPLC analysis of digested products of 23S rRNA platination was done by 
Dr. Hanna Hedman and Dr. Keshab Rijal. The experimental procedure was 
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summarized in detail in the thesis work of Dr. Keshab Rijal (181). In short, to 
evaluate the binding preferences of the two platinum complexes 
(monoaquated cisplatin and monoaquated Oplatin (2a)), 23S rRNA was 
incubated with approximately equimolar concentrations of metal complex and 
total guanosine content. Unplatinated and platinated RNAs were each 
digested with P1 nuclease for 14 h at 37 °C in 30 mM NaOAc, pH 5.2, and 250 
µM ZnCl2. The digested nucleotides were dephosphorylated with calf intestine 
alkaline phosphatase (CIAP) after addition of 10× CIAP reaction buffer 
(Promega) to a final concentration of 50 mM Tris-HCl (pH 9.3 at 25 °C), 1 mM 
MgCl2, 0.1 mM ZnCl2 and 1 mM spermidine. The resulting nucleosides were 
separated and analyzed by the HPLC program described in Section 3.3.6 
(above experiments were done by Dr. Hanna Hedman and Dr. Keshab Rijal). 
 
3.3.9 Liquid chromatography-mass spectrometry (LC-MS) 
LC-MS was carried out on an ACQUITY Ultra Performance Liquid 
Chromatography (UPLC) system (Waters Corporation, MA USA) with an 
HSST3 C18 column (1.8 μm particle diameter, 2.1 mm i.d. x 100 mm) coupled 
to a LCT Premier XE mass spectrometer(Waters, Milford, MA, USA). 
Acetonitrile and 100 mM NH4OAc, pH 6.0, were used as LC buffer. The column 
was maintained at 50 °C and elution was carried out with a linear gradient of 
acetonitrile and ammonium acetate buffer. The gradient was run for 3 min with 
a flow rate 700 µL/min, starting at 100% ammonium acetate and decreasing to 
65 
 
 
60% over the course of the gradient. The coupled mass spectrometer was first 
calibrated with the internal standard, dioctyl phthalate (DOP), before use. All 
LC-MS data were collected in the positive-ion mode. 
 
3.4 Results and discussion  
3.4.1 HPLC standard calibration of single nucleosides 
Figure 3.3. HPLC standard curves of U, C, A and G are shown. The detected peak area 
(mAU*sec) was plotted versus injected amount (pmole) and fitted to a linear equation. 
Each point is an average of three repeat with error bar indicated. 
In order to perform quantitative analysis from HPLC-UV, a series of 
standard calibration curves were obtained for the nucleosides. From the data 
shown in Figure 3.3, clear linear relationships were obtained for all four 
nucleosides with R factors greater than 0.99. In Figure 3.3, each data point 
66 
 
 
was an average of three injections, and the error bar is also indicated (in all 
cases, the error bars are smaller than the symbol representing each point). As 
shown in Figure 3.3, high reproducibility was observed with this LC method, 
even when the injections were made months apart. The four linear equations 
can therefore be used in future Pt reactivity studies for quantification of product 
yields.  
3.4.2 Quantitative LC analysis of digested products of 23S rRNA 
platination 
In order to evaluate the binding preferences of monoaquated cisplatin and 
Oplatin, the LC data of digested products of 23S rRNA were further analyzed 
using the standard curves (Figure 3.3), and the amount of each nucleoside in 
the sample was determined. In addition to the four standard nucleoside peaks, 
five product peaks in the chromatogram of nucleosides derived from 
cisplatin-modified rRNA were detected and compared to that of the unmodified 
RNA (Figure 3.4). Similarly, at least five product peaks were identified in the 
Oplatin sample, whose pattern differred from that of the cisplatin sample. The 
appearance of these peaks corresponded to a decrease in intensity of the 
standard nucleoside peaks. 
Uridine was used as an internal standard since it is the least reactive 
substrate among nucleosides for Pt(II)-based complexes (74). The relative 
nucleoside/uridine value was calculated by dividing the amount (pmole) of 
each nucleoside (A, U, G, and C) with the calculated pmole amount of uridine 
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Figure 3.4. HPLC analysis of rRNA nucleosides are shown. A) Overlaid HPLC 
chromatogram of rRNA nucleosides from digestion of unmodified (upper), 
cisplatin-modified (middle) and Oplatin-modified (lower) samples (181). The product 
peaks are indicated with arrows. B) The detected peak areas of unreacted rRNA 
nucleosides are summarized. C) By using the standard curves of RNA nucleosides, for 
each sample, the pmole amount of each nucleoside was calculated and normalized to 
the uridine amount.  
in the same sample. The HPLC results of the nuclease-digested unmodified 
and platinum-modified 23S rRNA reveal different binding preferences for the 
two platinum complexes (Figure 3.4). After modification of 23S rRNA with 
68 
 
 
cisplatin, the amount of guanosine was reduced by approximately 50% and the 
adenosine amount is reduced by 25% (Figure 3.4). These results suggest that 
cisplatin reacted primarily with purine residues, and G residues are the major 
target sites. After normalization, the cytidine amount was higher than the 
control. This result could occur if uridine is able to react with cisplatin, even 
through it has been reported as the least reactive substrate among 
nucleosides for Pt(II)-based complexes (74).  In contrast to the result with 
cisplatin, the detected adenosine amount in 2a-modified 23S rRNA sample 
was reduced by more than 50% while the guanosine amount in this case was 
only reduced by 25% compared to the unmodified rRNA. 
Based on LC-MS analysis, the product peaks in cisplatin-modified RNA 
sample were assigned as cisplatin-RNA intra-cross-linked adducts 
cis-[Pt{1,2-(GpG)}(NH3)2]+, cis-[Pt{1,2-(ApG)}(NH3)2]+, 
cis-[Pt{1,2-(GpG)}(NH3)2]+, and other bisfunctional adducts such as 
cis-[Pt(Guo)2(NH3)2]2+ and cis-[Pt(Ado)(Guo)(NH3)2]2+ (Guo = guanosine, Ado 
= adenosine) (181). Five potential product peaks in Oplatin-modified 23S rRNA 
sample were assigned as 2a-RNA monofunctional adducts such as 
[PtCl(Ado)(Orn)]+, [PtCl(Guo)(Orn)]+, [Pt(Ado)(H2O)(Orn)]+, bisfunctional 
adduct [Pt(Ado)(Guo)(Orn)]+ and intra-cross-linked adduct 
[Pt{1,2-(ApG)(Orn)}]+ (181).  
Overall, monoaquated cisplatin and Oplatin (2a) exhibit different sequence 
preferences for platination of large, structured RNA. More specifically, similar 
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to DNA, cisplatin exhibits a preference for guanosine over adenosine in RNA, 
whereas the opposite preference was found for Oplatin (2a). This result is 
consistent with the primer extension analysis on 23S rRNA (122) and further 
confirms Oplatin's altered sequence preference for A.  
 
3.4.3 Binding studies of Oplatin with single nucleosides 
Reactions of Oplatin (2a, 2b) with adenosine or guanosine in 1:1 molar 
ratios 
With the establishment of both qualitative and quantitative HPLC methods 
for the evaluation of amino-acid-linked cisplatin analogue reactivity towards 
RNA, reactions were then carried out between chosen cisplatin analogues and 
RNA purine nucleosides. Ratios of 1:1 mono- or bisaquated Pt 
complex:nucleoside were employed. The results with 2a and adenosine (Ado, 
A) are shown in Figure 3.5. Product peaks (19 and 21 min retention times) 
were observed within the first 10 min of incubation. After approximately 7 h 
incubation, two more product peaks were detected at retention times of 5 and 
6 min. Another small peak was observed at approximately 17 min. The results 
with bisaquated Oplatin, 2b, and adenosine (Ado, A) (Figure 3.6) were slightly 
different from those with monohydrated Oplatin (2a). Similar to the results 
shown in Figure 3.5, two major product peaks at 19 and 20 min retention times 
could be detected right after mixing; however, no product peaks at retention 
times of 5 and 6 min were detected. The same reactivity test was also carried 
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out with 2a and guanosine (Guo, G) (Figures 3.7 and 3.8). As shown in Figure 
3.7, a single dominant product peak (9 min retention time) was detected after 1 
h. As with the adenosine-2a reaction, additional product peaks (5 min retention 
time) were observed at longer reaction times (> 3 h). Compared with 2a, 2b 
showed similar reactivity towards guanosine (Figure 3.8). A single product 
peak (9 min retention time) was detected after the 1 h reaction time. 
The Oplatin reactivity profiles with RNA purine nucleosides as determined 
by HPLC analysis are summarized in Table 3.2. The major product peaks 
consistently eluted 1-2 min earlier than the unreacted nucleosides in the 
spectra due to the increase in polarity after platination. Based on the overall 
results, both mono- and bisaquated Oplatin (2a and 2b) demonstrate better 
reactivity and form multiple adducts with A compared to G. Competition 
reactions were carried out next to confirm this reactivity difference. 
 
Figure 3.5. HPLC results of time-dependent monoaquated Oplatin (2a) reaction with 
adenosine in a 1:1 molar ratio are shown. The left figure is the control without 2a. 
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Figure 3.6. HPLC results of time-dependent bisaquated Oplatin (2b) reaction with 
adenosine in a 1:1 molar ratio are shown. The left figure is the control without 2b. 
 
 
Figure 3.7 HPLC results of time-dependent monoaquated Oplatin (2a) reaction with 
guanosine in a 1:1 molar ratio are shown. The left figure is the control without 2a. 
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Figure 3.8. HPLC results of time-dependent bisaquated Oplatin (2b) reaction with 
guanosine in a 1:1 molar ratio are shown. The left figure is the control without 2b. 
 
Table 3.2: Retention times of guanosine, adenosine, and major platination products with 
2a and 2b are sumarized. 
  G G-Pt A A-Pt1 A-Pt2 
Retention Time 12-13 min 9-10 min 22 min 18-19 min 20-21 min 
 
Competition reactions of Oplatin (2a, 2b) with adenosine and guanosine  
in a 1:1:1 molar ratio 
In order to confirm Oplatin's reactivity and preference for adenosine over 
guanosine in RNA studies, a competition reaction of 2a with both adenosine 
and guanosine (1:1:1 molar ratio) was performed and analyzed by HPLC. As 
shown in Figure 3.9, the major products observed are derived from adenosine 
platination (retention times of 19 and 21 min). Adenosine product peaks were 
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detected immediately after mixing of the reaction components; whereas, the 
guanosine platination product were only be seen after 2-3 h of incubation.  
 
Figure 3.9. HPLC results of a competition reaction of monoaquated Oplatin (2a) reaction 
with adenosine and guanosine in a 1:1:1 molar ratio are shown. The left figure is the 
control without 2a. 
To summarize the results of the binding studies with HPLC analysis, mono- 
and bisaquated Oplatin (2a, 2b) can form multiple stable products with 
adenosine within a few minutes reaction time. The preference for A over G was 
also observed in the single nucleoside reactions, indicating that Oplatin (2) 
reactivity at A residues in h24 within the full-length rRNA may result from a 
nucleotide preference in addition to structural recognition of the RNA helix 
(122).  
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Figure 3.10 HPLC results of a competition reaction of bisaquated Oplatin (2b) reaction 
with adenosine and guanosine in a 1:1:1 molar ratio are shown. The left figure is the 
control without 2b. 
 
Reactions of excess Oplatin (2a) with adenosine or/and guanosine 
In order to have a more quantitative view with respect to reaction kinetics 
of 2a with individual nucleosides, the peak areas of adenosine or guanosine 
were analyzed following reactions with the platinum complex. As with reaction 
profiles shown in Figures 3.9 and 3.10, excess 2a was reacted with 
adenosine or guanosine separately in different molar ratios. A control sample 
without platinum complex was prepared for each nucleoside reaction under the 
same reaction conditions. At each 2 h time point of the reaction, both control 
and platinum-containing reactions were analyzed by HPLC to obtain the peak 
areas of unreacted nucleoside. As indicated in Equation 3.2, the peak area of 
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unreacted nucleoside in each platinum sample was divided by the nucleoside 
peak area in the control as the fraction of unreacted nucleoside remaining in 
the reaction mixture (Figure 3.11).   
 Equation 3.2 
in which Y is unreacted nucleoside fraction. 
 
 
Figure 3.11. Excess 2a reactions with adenosine (left) or guanosine (right) were 
quantified and plotted as a function of reaction time. 
 
When incubated with at least 10-fold excess 2a, the decrease of 
unreacted adenosine in the reaction mixture was significantly faster than for 
guanosine. After 6 h of incubation, less than 50% of unreacted adenosine 
remained. For guanosine, more than 75% of the unreacted nucleoside was left 
at the same time point and ratio. After 10 h, the reactions carried out with a 
1:50 ratio of nucleoside:Pt contained less than 10% unreacted A, whereas, 40% 
unreacted G was detected. Competition reactions with excess Pt and both G 
and A present were also carried out, and the data are shown in Figure 3.12 
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with direct comparison of G and A reactivity. 
 
Figure 3.12. Competition reactions of excess monoaquated Oplatin (2a) with adenosine 
and guanosine were quantified and plotted as a function of reaction time (unreacted 
adenosine (■); unreacted guanosine (□)). 
The competition reactions with both purine nucleosides present and 
10-fold or 50-fold excess monoaquated Oplatin (2a) showed a very clear 
preference for A (Figure 3.12). From the 0 to 10 h time points, the decrease of 
adenosine was always faster than G in both reactions. This result further 
supports the preference of 2a for A over G, which is opposite of the reactivity 
preference of cisplatin. 
 
3.4.4 Preliminary product analysis of Oplatin with adenosine 
As mentioned previously, Oplatin (2) can form multiple adducts with 
adenosine under short incubation times, and has a clear preference for A over 
G. In order to further analyze the structures of platinated products, LC-MS 
analysis was carried out on an overnight reaction between monoaquated 
Oplatin (2a) and adenosine. 
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Figure 3.13. LC-MS analysis of monoaquated Oplatin (2a) with adenosine is shown. The 
HPLC trace is shown in panel A. Mass spectra were collected in the positive ion mode 
(panels B-G) for each peak at the various retention times indicated. The isotope 
distribution is shown in the expanded peak insets. 
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As shown in Figure 3.13A, six peaks were detected by LC and the 
corresponding mass data are given. The last peak in the LC spectrum at 2.24 
min is assigned as unreacted adenosine based on the mass data and 
comparison to control adenosine (Figure 3.13B). The two product peaks at 
1.89 and 2.03 min retention times have the same mass of 629.1 m/z, both with 
typical platinum isotope distributions (Figure 3.13C and D). The three product 
peaks at 0.61, 0.80, and 0.89 min (Figure 3.13E, F and G) all have a mass of 
691.1 m/z.  
Based on the mass data of adenosine and Oplatin (2), and consistent with 
previous literature (122,181), the structures shown in Figure 3.14 are 
proposed. There are three nitrogen atoms in adenine available for Pt 
coordination, which explains the multiple product peaks in the HPLC trace from 
the reaction between 2a and adenosine. All platination reactions were carried 
out in 25 mM sodium phosphate buffer and 5 mM NaCl. The phosphate 
concentration is four-fold higher than Cl-. As a result, phosphate coordination 
to Oplatin is also possible. 
A potential hydrogen bond exists between the carboxylate oxygen of 
Oplatin and N6-H of adenosine, which may explain why only two major 
products are observed at the shorter reaction times. This hydrogen bond would 
stabilize coordination at the N1 or N7 position of adenine. We hypothesize that 
steric factors and the absence of stabilizing hydrogen bonding would disfavor 
A-N3 coordination to 2a. Previous research to characterize cisplatin-DNA  
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Figure 3.14. Structures and calculated masses of 2a, adenosine, and proposed products 
for species with 0.61, 0.80, 0.89, 1.89 and 2.03 min HPLC retention times are shown.  
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products showed hydrogen-bonding interactions between the amine group on 
cisplatin and O6 of guanine, leading to cisplatin's preference for guanosine 
over adenosine (74, 88). Based on this information, we hypothesize that the 
Oplatin preference for A over G is due to a similar mechanism, but with 
differing hydrogen-bonding interactions. Therefore, we propose that the two 
major products observed when Oplatin reacts with adenosine correspond to 
structures 5a and 5b in Figure 3.14. Further studies to confirm this hypothesis 
are discussed later in this thesis. 
 
3.4.5 Binding studies of Gplatin (1) with single nucleoside 
In addition to Oplatin, Gplatin (1) reactivity with RNA nucleosides was also 
characterized. The binding studies were performed as described in Section 
3.3.3. Compared to Oplatin, Gplatin has no side chain and also has one less 
positive charge. In the reaction of monoaquated Gplatin (1a) with adenosine, 
two product peaks were observed with similar retention times as those of 
Oplatin (Figure 3.15). The rates of increase of product peak area with 
corresponding decrease of unreacted adenosine over time were slower 
compared to 2a, implying a weaker reactivity of 1a towards RNA nucleosides.  
In the reactions of monoaquated Gplatin (1a) with guanosine (Figure 
3.16), two major product peaks were observed on reverse-phase HPLC, with 
shorter and longer retention times than guanosine. In general, Gplatin (1) 
demonstrated similar reactivity towards RNA purine nucleosides as Oplatin (2) 
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in terms of the number of products, but some differences were observed with 
respect to reaction rates and product structures or behaviors on the HPLC 
column. 
 
Figure 3.15. HPLC result of time-dependent monoaquated Gplatin (1a) reaction with 
adenosine in a 1:1 molar ratio is shown. The left figure is the control without 1a. 
 
Figure 3.16. HPLC result of time-dependent monoaquated Gplatin (1a) reaction with 
guanosine in a 1:1 molar ratio is shown. The left figure is the control without 1a. 
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Figure 3.17. Results from a competition reaction of monoaquated Gplatin (1a) with 
adenosine and guanosine in a 1:1:1 molar ratio were shown. The left figure (A) is the 
control without 1a.  
Since the Oplatin (2) preference for adenosine was hypothesized to occur 
because of a potential hydrogen bond between its carboxylate group and 
adenosine N6-H, Gplatin was expected to have a similar reaction preference 
towards A with the same five-membered ring coordination pattern. In a 
competition reaction of monoaquated Gplatin (1a) with both purine nucleosides 
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present (Figure 3.17A), five product peaks were detected after 30 min, then 
two more product peaks appeared after extended reaction times (9 h). The 
fractions of nucleoside remaining in the reaction mixture were also determined 
by comparing the peak area of the nucleoside in the sample with the peak area 
of nucleoside in the control (no Gplatin) (Equation 3.2). As seen in Figure 
3.17B, Gplatin also demonstrates an A preference. This competition reaction 
was only carried out once. The reaction appeared to reach its first equilibrium 
(for monofunctional adduct formation) after 1 h (Figure 3.17B); no decrease in 
unreacted nucleoside amount was observed during the 1 to 5 h time points. 
Although this result needs to be repeated, we believe that it supports our 
hypothesis that the preference for A is due to a hydrogen-bonding interaction 
between the amino acid carboxylate and A N6-H. 
 
3.5 Future directions 
Coordination of aquated forms of Oplatin (2) and Gplatin (1) with RNA 
nucleosides reveals unexpected reactivity and binding preferences for 
adenosine in both full-length rRNA and in the context of free nucleosides. This 
preference differs from that of cisplatin, which coordinates mainly to guanosine 
residues. These results indicate that the RNA reactivity of Pt(II)-based 
complexes can be tuned by altering the carrier ligands. By characterizing the 
Oplatin-RNA products at the nucleoside level, we can understand the role of 
the ligands in platinum reactivity, and separate this activity from the influence 
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of RNA secondary or tertiary structure. The information gained from this study 
will contribute to the current profile of chemical modifications of cisplatin 
analogues to improve their selectivity or to develop more effective metal-based 
chemical probes or drugs. 
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CHAPTER 4  
Product characterization and kinetic studies of Oplatin with 
RNA nucleosides 
4.1 Abstract  
The role of RNA in the life cycle of the cell is highlighted by protein 
synthesis, in which ribosomal RNA is essential. Therefore, the ribosome is 
considered to be an ideal drug target. Platinum-based complexes have been 
reported as chemical probes to determine solvent accessibility of rRNAs in 
vivo and in vitro, and the reactivity can be tuned by altering the carrier ligand(s) 
to amino acids, such as ornithine (Oplatin, 2). In order to further understand 
the mechanism behind Oplatin's altered reactivity, the work in this chapter 
focused on the reactivity and product profile of 2 with nucleosides by using 
high performance liquid chromatography (HPLC), nuclear magnetic resonance 
(NMR) spectroscopy, and mass spectrometry (MS). Based on these results 
and previous literature, we have gained a better understanding on how the 
ligands alter the reactivity of Pt(II) compounds.  
 
4.2 Introduction 
Since the discovery of cisplatin's antitumor property, its reactivity to 
nucleosides and nucleic acids has been studied intensively (88, 139, 184). The 
N7 position of a deoxyguanosine residue was shown to be the primary target 
site of cisplatin, with deoxyadenosine as a minor coordination site (74, 88). 
86 
 
 
Based on a theoretical study, the preference of cisplatin for G over A was 
attributed predominantly to a strong hydrogen bond between the ammine 
ligand of the metal complex and the 6-oxo group of guanine (185). The 
Pt-adenine adduct, in which either the Pt-ammine or chlorido ligand serves as 
the hydrogen-bond donor, is energetically less favorable compared to the 
Pt-guanine adduct (185) (Figure 4.1). 
 
Figure 4.1. Optimized structures of cisplatin platination products with guanine (top) and 
adenine (bottom) are shown (185). Geometries were optimized using Jaguar and the 
B3LYP functional (186, 187), with the 6-31G** basis set. Platinum was represented by 
the Los Alamos LACVP** basis (188-190), which includes relativistic effective core 
potentials. The lowest energy structure was determined by additional single point 
calculations using Dunning’s correlation consistent triple-ζ basis set cc-pVTZ(-f) (191) 
with the standard double set of polarization functions; the potential H bonds (dashed 
lines) and bond lengths indicated.  
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Figure 4.2. An example of radioactive labeling and primer extension for platination 
residue identification in RNA is given. (A) A schematic illustration of ddNTP sequencing 
of RNA is shown. (B) A schematic illustration of reverse transcription (RT)-based primer 
extension of Pt(II)-modified RNA is given. (C) Gel electrophoresis analysis of the 
sequencing and probing results is illustrated. The observed modified site (stop) on the 
gel is one nucleotide prior to the actual modified site. 
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In the previous chapter, Oplatin (2) demonstrated a clear preference for 
adenosine over guanosine, within the loop or bulge regions of RNA (122). This 
result suggests that Oplatin (2) is a promising candidate not just as a chemical 
probe that is complementary to cisplatin, but also as a potential RNA-targeting 
anticancer drug. Product characterization of the Oplatin-nucleoside adducts 
will offer insight into compound selectivity, and will provide an improved point 
of view regarding the ligand effects on Pt(II) reactivity without interference from 
the RNA higher-order structure (185). Previous studies on RNA-Pt(II) adducts 
focused on identification of platination sites using methods such as radioactive 
labeling, primer extension, and enzymatic footprinting (summarized in Figure 
4.2); however, there is little information about the chemical structures of the 
RNA-Pt(II) adducts from these studies (117, 118, 192-195).  
In the work reported in this chapter, we further evaluated Oplatin reactivity 
at the nucleoside level using HPLC, NMR spectroscopy, and MS. These 
Oplatin-nucleoside product profiles are expected to give a better 
understanding of how the ligands alter Pt(II) reactivity, and will assist in the 
design of RNA-targeting Pt(II) complex design. 
4.3 Materials and methods 
4.3.1 General 
All chemicals and reagents were purchased from Sigma-Aldrich or Fisher, 
unless otherwise stated (Section 3.3.1). Deuterium oxide (99.9 atom% D) was 
purchased from Cambridge Isotope Laboratories, Inc. The C8-13C labeled 
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adenosine was a generous gift from Dr. Jun Jiang and Dr. John SantaLucia. 
RNase-free, distilled, deionized ddH2O (Millipore water) was used throughout 
the experiments.  
 
4.3.2 Product isolation 
The stock solution of adenosine or guanosine was prepared fresh for each 
platination reaction, and the concentration was determined using UV-visible 
spectroscopy as described in Section 3.3.3. Oplatin (2) was monoaquated to 
2a right before each reaction. The platination reaction was prepared with 1:1 
Pt:nucleoside ratio and the reaction conditions are summarized in Section 
3.3.5. For product isolation, each platination reaction was carried out for 12 h 
before quenching (Section 3.3.5) and the sample was stored at -80 °C until 
further analysis. The product fractions were isolated using the HPLC program 
described in Section 3.3.6. The isolated fractions were dried and stored at 
-20 °C. 
 
4.3.3 Mass spectrometry 
MS analysis was performed on a 7T Bruker SolariX Fourier Transform Ion 
Cyclotron Resonance Mass Spectrometer (FT-ICR) in the Rodgers' laboratory. 
Data collection was done with the help of Dr. Zhihua Yang. All mass spectra 
were obtained in the positive-ionization mode. The protonated 
Oplatin-nucleoside adducts were generated by an electrospray ionization (ESI) 
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source from the solutions of 0.01 mM sample dissolved in 50%:50% 
methanol:water. Direct infusion ESI experiments were performed at an infusion 
rate of 2 µL/min. The nebulizing (NZ) drying gas temperature was set at 180 °C 
with a flow rate of 4 L/min, and held at 1.2 bar. The ESI capillary voltage was 
set between −3.5 and −4.5 kV. Tandem mass spectra (MS/MS) of the product 
ions of interest were generated by collision-induced dissociation (CID) of the 
trapped precursor ions (argon collision gas). The fragmentation amplitudes 
varied from 0.4 to 1.0 V, and the isolation width was 4.0 m/z. All data and 
simulated spectra were analyzed using the DataAnalysis 4.1 software (Bruker 
Daltonics). 
 
4.3.4 NMR spectroscopy 
The 1H and 13C NMR (700 MHz) spectra of Pt(II)-nucleoside adducts and 
reaction kinetics were recorded on a Bruker Avance 700 MHz spectrometer 
equipped with a TXI cryoprobe (Lumigen Instrument Center). Data collection 
was done in collaboration with Dr. Jun Jiang. In order to differentiate the H8 
and H2 signals in adenosine, C8-13C labeled adenosine was used (Section 
4.3.2). The C2 and C8 signals of adenosine were identified by their chemical 
shifts. Ten μM trimethylsilyl propionate (TSP) was added to each sample as 
the internal standard.  The 1H chemical shifts were referenced to the residual 
HDO (semi-heavy water) signal, which was calibrated against TSP. For the 1H 
and 13C NMR (700 MHz) spectra of Pt(II)-nucleoside adducts, D2O was chosen 
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as the solvent without buffer. 
Solutions from the kinetic studies were initially prepared in H2O and then 
transferred into D2O by solvent replacement (i.e., dry the sample under 
vacuum and then re-dissolve in D2O). Oplatin (2) was converted to the 
monohydrated form (2a) by reacting with AgNO3 in a 1:0.7 molar ratio in D2O 
for 5 h in the dark. Then, the white precipitate, AgCl, was removed by 
centrifugation twice at 12,000 RPM for 10 min. Monoaquated Oplatin (2a) was 
freshly prepared before each experiment. The platination reaction was carried 
out in 25 mM sodium phosphate buffer, pH 7.0, at 37 °C. The concentration of 
nucleoside was 100 μM, and that of 2a was 5 mM. The TSP standard was 
added to each sample to a final concentration of 10 μM for calibration of proton 
chemical shifts and peak integrations. A 1D version of nuclear Overhauser 
effect spectroscopy (NOESY) with presaturation during relaxation delay and 
mixing time (noesypr1d) was used to acquire the 1D 1H spectra at 37 °C. Data 
collection was run for 6 min and 50 sec (128 scans). Each reaction was carried 
out in duplicate. Data were processed with TOPSPIN 2.1 (Bruker Biospin). The 
percentage of the unreacted nucleobase proton signal was calculated as a 
function of time by using Equation 4.1.  
 Equation 4.1 
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As shown in Scheme 4.1, the data were fitted to a pseudo-first-order 
exponential decay: Y = A exp(−kobs X), in which, Y is the unreacted fraction, 
and X is the reaction time. 
Scheme 4.1. Reaction scheme for Pt(II)-nucleoside kinetic studies. 
 
 
4.3.5 Ultraviolet (UV) spectroscopy 
An Aviv 14DS UV-visible spectrometer in Dr. David Rueda's laboratory was 
used for all UV measurements. The isolated platinated nucleoside was 
dissolved in 25 mM NaH2PO4/Na2HPO4, pH 6.0. The sample temperature was 
kept at 37 °C for all measurements. Extinction coefficients were given in 
Chapter 3, Section 3.3.3. 
 
4.4 Results 
4.4.1 Product characterization of Oplatin (2) reactions at the 
nucleoside level 
4.4.1.1 Mass spectrometry analysis 
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Figure 4.3. HPLC (C18) analysis of reactions of monoaquated Oplatin (2a) with (A) 
adenosine, or (B) guanosine, in a 1:1 molar ratio is given. 
The 2a-nucleoside reaction products were separated by using 
reverse-phase (C18) HPLC-UV as discussed in Section 3.3.6. The individual 
fractions were collected and subjected to mass spectrometry (in the 
positive-ion mode) for characterization. Two major product peaks (Figure 4.3, 
referred to as A1 and A2), with retention times of 19.8 and 21.6 min, 
respectively, were identified in the chromatograph of the adenosine-2a 
reaction. The guanosine-2a mixture gave only one major product peak (Figure 
4.3, referred to as G1) with a retention time of 10.8 min. The same product 
profile was revealed in 2a reactions with a mixture of adenosine and 
guanosine (1:1:1 molar ratio, Figure 3.9). Relative abundances of the A 
adducts were also deduced from the reverse-phase HPLC profile (Figure 4.3). 
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The A product peaks have similar abundances (A1, 23%; A2, 22%) and 
appeared simultaneously in the reaction time profile. With higher hydrophilicity, 
all of the platination products eluted before the unreacted nucleosides. The LC 
results indicate that 2a forms multiple stable adducts with adenosine over a 
short reaction time. As described in Chapter 3, Oplatin has a strong 
preference for reactions with adenosine over guanosine (122).  
 
Figure 4.4. The 2a-nucleoside reaction products were analyzed by MS in the positive-ion 
mode. 
Mass spectrometry analysis (Figure 4.4) confirmed the formation of 
2a-nucleoside adducts, based on the m/Z values and signature Pt isotope 
distribution (details of peak assignments are given in Table 4.1 and Figure 
4.5). The data indicate that monofunctional platination adducts are the major  
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Table 4.1. The detailed assignments of the mass spectra of 2a-nucleosides adducts (the 
chemical formulas are given for the major product peaks; others are indicated as 
fragments of the major products.)  
 
(Orn = ornithine; Ado = adenosine; Guo = guanosine) 
species in each of the isolated fractions. A pronounced peak with m/Z 629.1 
was observed in both mass spectra of the adenosine reaction fractions A1 and 
A2 (Figure 4.4). These products were assigned as monofunctional adducts of 
2a with A (m/z: calcd. 629.1; obsd. 629.1), likely resulting from coordination at 
different nucleobase nitrogens, N1 and N7. Similarly, a dominant peak was 
detected in the G1 fraction and assigned as a monofunctional adduct of 2a 
with G(m/Z calcd. 645.1; obsd. 645.1, Figure 4.4).  
Combining mass and HPLC data for reactions of 2a with A, some 
preliminary assignments could be made. At the nucleoside level, Pt(II) 
complexes normally show high coordination ability with both the N1 and N7 
positions of adenosine (195-197). In double-stranded DNA and RNA, however,  
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Figure 4.5. The structures of hypothesized monofunctional 2a adducts with guanosine  
or adenosine are shown (Orn = ornithine; Ado = adenosine; Guo = guanosine, μ: 
bridging ligand).  
the A-N1 position is involved in Watson-Crick base pairing, therefore less 
accessible than A-N7. In previous probing studies, 2a was highly reactive 
towards adenosine residues in the single-stranded regions of RNA, which 
implied that 2a could be more reactive towards the adenosine N1 in RNA (122). 
Since the A-N7 is not involved with Watson-Crick base pairing, its accessibility 
would be expected to be similar in single-stranded and double-stranded 
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regions of the RNA, although the possibility of its involvement in RNA tertiary 
structure can not be excluded. Furthermore, the N7 of purines in RNA is 
generally less accessible compared to DNA due to the deeper and more 
narrow "major" groove of RNA. 
Based on the mass data (Figures 4.4, 4.5, and Table 4.1), as well as the 
elution time and fraction abundance (Figure 4.3), the major species in the 
A1and A2 fractions were assigned as A-N1 or A-N7 Pt-coordinated 
monofunctional adducts, [PtCl(N1-Ado)(Orn)]+ or [PtCl(N7-Ado)(Orn)]+. It 
should be noted that electrospray MS (Figure 4.4 and Table 4.1) also 
identified minor products within the A1 and A2 fractions, including a 
bifunctional adduct, [Pt(Ado)2(Orn)]+ (m/z: calcd. 860.2; obsd. 860.2; Ado = 
adenosine) and a doubly platinated adenosine adduct, [(PtCl(Orn))2(N1, 
N7-Ado)]+, (m/z: calcd. 990.1; obsd. 990.1) (Table 4.1 and Figure 4.6 A).  
Tandem mass spectrometry and simulated spectra were used to assign 
the composition of the minor products of the 2a reaction with adenosine 
(Figure 4.6). In each of the 2a-adenosine product fractions, more than one 
product type was identified with a monofunctional adduct as the major species. 
Further analysis, in which isolated fractions A1 and A2 were reinjected onto 
reverse phase HPLC, suggested that the minor products in each of the HPLC 
fractions were produced during the reaction and co-eluted  with the major 
adducts (an asymmetric peak shape was observed with both the A1 and A2 
HPLC fractions, Figure 4.7).  
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Figure 4.6. Based on the proposed chemical formula of 2a-adenosine minor adducts 
from fractions A1 and A2, the experimental and simulated spectra of m/Z 990.1 and 
860.2 are compared (A). (B) CID analysis of m/Z 860.2 in the positive-ion mode. The 
fragmentation patterns match the proposed chemical composition of [Pt(Ado)2(Orn)]+ 
(Orn = ornithine; Ado = adenosine, μ: bridging ligand).  
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Figure 4.7. HPLC chromatographs show isolated A1 and A2 fractions reinjected on a 
reverse phase C18 column after NMR and MS analysis. 
 
4.4.1.2 NMR analysis 
Proton and 13C NMR spectroscopy was used to further identify the 2a 
coordination site(s). Previous analysis of monofunctional deoxyadenosine 
adducts of cisplatin by Eastman showed that the more hydrophilic product 
eluted earlier in reverse-phase HPLC, which was assigned as the N1 adduct 
due to a major chemical shift change (~ 0.5 ppm) of the H2 proton upon 
platination (195). The other product was assigned as the N7 adduct due to the 
observed 0.4 ppm downfield shift of the H8 peak (195). C8-13C-labeled 
adenosine was used in our initial NMR studies in order to confirm the 
assignment of the H8 signal (Figure 4.8A). The peaks for the H8 and H2 
protons of fractions A1 and A2 were assigned by employing 2D heteronuclear 
multiple quantum correlation (HMQC) spectroscopy in collaboration with Dr. 
Jun Jiang (Figure 4.8A). Even though the chemical shifts of the adenosine H8 
and H2 protons are located in the same region, they can  
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Figure 4.8. The 2D heteronuclear multiple quantum correlation (HMQC) experiments 
were run on the adenosine control (green), A1 (blue), and A2 fraction (red), at 37 °C. The 
C8-H8 and C2-H2 regions of the overlaid spectra (A) were shown in upper and lower 
panels, respectively. The chemical shifts of C8 and C2 were used to assign the chemical 
shifts of H8 and H2. The aromatic region of 1D proton NMR spectra (B and C) of the 
isolated 2a-nucleoside products is shown for: (B) adenosine (upper), A1 (middle), and 
A2 (lower), and (C) guanosine (upper) and G1 (lower). Proton signals for A-H8, A-H2 and 
G-H8 are noted with triangles, circles, and stars, respectively. 
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be differentiated by coupling to the C8 and C2 carbon atoms, respectively. The 
peaks corresponding to C8 are between 140 and 145 ppm for adenosine and 
product A1 and A2, and those of C2 are downfield shifted to 152-157 ppm. In 
the HMQC spectra, crosspeaks between C8 and H2 or C2 and H2 are 
observed. From the chemical shift of the carbon atom to which the proton is 
attached, an H8 can be differentiated from an H2 proton. 
In the 1D 1H spectrum for minor products of fraction A2 (Figure 4.8B, 
lower), both A-H8 (triangles, open and closed for major products) peaks were 
downfield shifted by approximately 0.5 ppm, while the corresponding changes 
of A-H2 chemical shifts were only 0.1 ppm. The stronger deshielding effect 
observed for the two A-H8 signals suggests that platination occurs on the 
neighboring A-N7 for both products. The dominant signal set (closed symbols) 
was assigned as the monofunctional A-N7 adduct, and the other set (open 
symbols) was assigned to the bifunctional adduct [Pt(Ado)2(Orn)]+, with 
coordination to both N7 positions (Figure 4.6). In the 1D 1H spectrum of 
fraction A1 (Figure 4.8B, middle), two sets of A-H8 and A-H2 peaks were 
clearly shown in a pattern that differs from that of the A2 fraction. The major 
peak corresponding to H8 only showed a small chemical shift change (< 0.1 
ppm, A-H8, marked with a closed triangle), whereas the other showed a 0.5 
ppm downfield shift (A-H2, marked with a closed circle), which suggested that  
the metal center is most likely coordinated to A-N1 (185, 195). For the set of 
minor peaks those corresponding to A-H2 (open circle) and A-H8 (open 
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triangle) signals were shifted downfield by about 0.5 ppm (Figure 4.8B, 
middle). These products were assigned to the A-N1 monofunctional adduct 
and doubly platinated adenosine with coordination of both the N1 and N7 
positions (Figures 4.5 and 4.6A, [(PtCl(Orn))2(N1, N7-Ado)]+, m/Z: calcd. 
990.1; obsd. 990.1, μ: bridging ligand), respectively.  
In contrast to the results with adenosine, the G1 fraction showed only one 
peak corresponding to the guanosine H8 (asterisk, Figure 4.8C, lower). The 
0.5 ppm downfield shift of this resonance was suggestive of G-N7 platination. 
Overall, the NMR results combined with MS data allowed for further 
identification of the 2a-nucleoside products. The HPLC peaks referred to A1 
and A2 are predominantly A-N1 or A-N7 platinum adducts, respectively; G1 is 
a G-N7 monofunctional adduct. The NMR spectrum of the G1 fraction (Figure 
4.8C, lower) does not show any minor products. This result is also consistent 
with the mass data.  
 
4.4.1.3 UV spectroscopy analysis 
The coordination sites of 2a-nucleoside products were also corroborated 
by ultraviolet (UV) spectroscopy. The λmax of each fraction, A1 and A2, was 
compared with the corresponding methylated nucleoside (Figure 4.9). As 
previously reported, cisplatin coordination to the nucleoside can cause a 
similar shift in the λmax as methylation (195), which would also allow for UV 
spectroscopy as a detection method for monitoring the platination reaction  
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Figure 4.9. Ultraviolet spectral patterns of 2a-nucleoside product fractions are shown 
(A), and (B) their λmax are compared to the λmax values of corresponding methylated 
nucleosides from the literature (16). 
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(192, 194). Comparing to data published on cisplatin effects on DNA 
nucleosides (195), a similar correlation was observed with the Oplatin reaction 
with RNA nucleosides. Compared to the λmax (260 nm) of adenosine, the 
A-N7-platinum adduct (A2) exhibited red-shifted absorption maximum at 263 
nm (Figure 4.9A, upper), similar to N7-methyladenosine (Figure 4.9B, a red 
shift to λmax=267 nm) (16). The A1 fraction (A-N1 adducts) revealed an 
absorption maximum at 258 nm, which is consistent with methylation on the 
same site (a characteristic λmax at 258 nm) (16). The absorption maximum for 
G-Pt (fraction G1) occurred at 257 nm, similar to N7-methylguanosine (16).  
The UV absorption spectra showed that 2a and methylation have similar 
effects on the UV spectroscopic characteristics of ribonucleosides, and also 
demonstrate that UV spectroscopy could be used as a characterization 
method for future nucleoside-level platination studies. Alkylation sites in RNA 
have been shown to cause cytotoxicity and contribute to the anticancer activity 
of alkylating drugs (198). Dimethylsulfate (DMS) is a known methylation 
reagent that is commonly used as a chemical probe for RNA structures and 
dynamics. Similar effects of Oplatin and methylation on the UV spectroscopic 
characteristics of nucleoside show the potential of 2a as a chemical probe and 
drug candidate in future RNA-related studies. 
 
4.4.2 Kinetic characterization of Oplatin-nucleoside reactions 
The binding of platinum compounds to nucleic acids has been shown to 
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be kinetically controlled (140, 184). The Bierbach group previously reported an 
A-coordinating Pt(II) compound with a template-dependent preference to A 
(199-201). To establish the kinetic preference of monoaquated Oplatin (2a) for 
various nucleosides, the rates of 2a and monoaquated cisplatin reacting with 
adenosine and guanosine were determined using 1D 1H NMR spectroscopy in 
parallel (in collaboration with Dr. Jun Jiang). A 50-fold excess of the Pt 
compounds were used to ensure pseudo-first-order reaction conditions. The 
percentage of the unreacted nucleobase proton signal was calculated as a 
function of time (Section 4.3.4).  
The results (Figure 4.10A) showed that 2a reacted with adenosine 12 
times faster (k=(69 ± 8) x 10-6 S-1 vs. (5.6 ± 2.1) x 10-6 S-1) than monoaquated 
cisplatin under the given conditions. In contrast, the reaction of 2a with 
guanosine was 1.5-fold slower (k=(17 ± 2) x 10-6 S-1 vs. (25 ± 2) x 10-6 S-1) than 
cisplatin. In the NMR spectra of adenosine reacting with 2a at different time 
points (Figure 4.10B), the proton signals corresponding to the assigned 
monofunctional adducts were observed first, and then the doubly platinated 
and bifunctional products appeared after 2 h. This further supports the peak 
assignments in Figures 4.8 and 4.9, since the doubly platinated or bifunctional 
products result from a second reaction with the substitution on monofunctional 
adducts. Since both of the above-mentioned experiments were carried out at 
the nucleoside level without any influence from the structure of RNA, Oplatin (2) 
is the first reported Pt(II) compound with a template-independent A preference.  
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Figure 4.10. (A) Reactions of single nucleosides ◆(▲: adenosine, : guanosine) with a 
50-fold excess (pseudo-first-order) of monoaquated cisplatin or 2a were monitored by 
1H NMR spectroscopy. Data were fitted to a first-order exponential decay and k values 
were determined. (B) The 1D 1H NMR spectra overlay of the aromatic proton regions of 
adenosine with 50-fold excess 2a reaction are shown. All peaks were normalized with 
the proton peak of TSP. 
 
 
107 
 
 
4.5 Discussion 
In this chapter, we first presented the adduct characterization of Oplatin (2) 
with adenosine and guanosine. The assigned product structures are 
summarized in Figure 4.11. A kinetic study was also carried out to characterize 
the A selectivity of 2. Monoaquated Oplatin (2a) was shown to form two major 
products with adenosine (the A1 fraction is assigned to [PtCl(N1-Ado)(Orn)]+ 
(5a) and the A2 fraction is assigned to [PtCl(N7-Ado)(Orn)]+ (5b)) and one 
major adduct with G (the G1 fraction is assigned to [PtCl(N7-Guo)(Orn)]+ (7)). 
Doubly platinated ([(PtCl(Orn))2(N1,N7-Ado)]+) and bifunctional 
([Pt(N7-Ado)2(Orn)]+) adducts were also observed as minor products in the 
2a-adenosine reaction. Oplatin is reported here to be the first Pt(II) compound 
with template-independent kinetic preference for adenosine when reacting with 
RNA. Cisplatin's selectivity for G in DNA has been attributed predominantly to 
a strong hydrogen bond between the ammine ligand and 6-oxo group of 
guanine (185); Oplatin's preference can be explained by an alternative 
hydrogen bond between the carboxylate group of 2 and 6-amine group of 
adenine.  
Based on the kinetic trans effect, we propose that Oplatin coordinates to 
the nucleoside in a trans fashion with the α-amine group and nucleoside N1 or 
N7 (202-204). When binding at the A-N1/N7 position, the 6-amino group in 
adenosine could form hydrogen-bonding interactions with the carboxylate 
ligand on Pt, whereas this structure would not be available in the guanosine 
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Figure 4.11. Assigned 2a product structures with nucleosides are shown (Orn = 
ornithine; Ado = adenosine; Guo = guanosine, μ: bridging ligand).  
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adduct (Figure 4.11). Steric factors and the absence of a stabilizing hydrogen 
bond could also explain the lack of A-N3 coordination for both Oplatin and 
cisplatin. The differences between Oplatin and cisplatin in both their chemical 
structures and sequence selectivity support the Lippard hypothesis and 
preference of cisplatin to G over A (185). This theory is valuable for future 
Pt-based chemical probing work and drug design, while other nucleoside 
selectivity (pyrimidines) needs to be achieved.  
For analogue coordination at N1 or N7 of adenosine, identifying new 
compounds with preferred reactivity at the N1 position could be a promising 
direction for selective RNA targeting by Pt compounds, since DNA is generally 
lacking single-stranded regions, and its A-N1 would therefore be expected to 
be unreactive. Combining the previous probing studies (122) and work in this 
chapter, Oplatin has been proven to be a useful RNA structure probe with 
sequence complementarity to cisplatin. We have also demonstrated that this 
compound has the potential to be a selective RNA-targeting drug if the 
preference for N1 over N7 of A can be achieved through ligand modifications. 
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CHAPTER 5  
Tandem mass spectrometry analysis of Oplatin and 
Oplatin-nucleoside adducts* 
 
* This work was carried out in collaboration with Chenchen He, Dr. Zhihua 
Yang, Dr. M.T. Rodgers, and the FELIX facility at the University of Nimengen, 
the Netherlands. 
 
5.1 Abstract 
Tandem mass spectrometry (MS/MS) is an effective and powerful 
technique that is widely used in current proteomic methodologies; however, 
MS/MS techniques in RNA-related research are not as well established. In the 
work presented in this chapter, different MS/MS techniques (collision induced 
dissociation, survival yield analysis, and infrared multiphoton dissociation 
spectroscopy) were applied to the study of amino-acid-linked cisplatin 
analogues (Gplatin, 1 and Oplatin, 2) to obtain further structural information. 
They were also utilized in the product characterization of monoaquated Oplatin 
(2a) reaction with adenosine and guanosine. MS/MS analysis has provided 
new information that is complementary to the data obtained from nuclear 
magnetic resonance (NMR) spectroscopy and high performance liquid 
chromatography (HPLC).  
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5.2 Introduction 
Mass spectrometry (MS) has played a key role in drug discovery (205). 
Tandem mass spectrometry (MS/MS) has also emerged as a powerful tool in 
protein structural biology over the last two decades (APPENDIX) (206). 
Tandem MS is a sensitive, high-resolution method with wide applications in 
proteomics; however, to date it has played only limited roles in RNA-related 
research.  
In this work, we first applied the collision induced dissociation (CID) 
technique to obtain further structural information on Pt(II) complexes, 1 and 2, 
and the 2a-nucleoside adducts discussed in previous chapters (Chapter 2, 3 
and 4). CID is an effective MS/MS method used to induce direct collisions 
between sample molecules and rare gas atoms, and applied frequently in the 
analysis of peptides and proteins (CID mechanism, APPENDIX) (207, 208). In 
this study, our goal was to use CID to gain information about the glycosidic 
bond strengths of nucleosides and various platinum adducts. 
 
Figure 5.1. A schematic diagram of the glycosidic bond and depurination reaction is 
given. 
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The effect of platination on stability of the nucleoside glycosidic bond has 
been a focus of cisplatin-DNA studies (203). Depurination (Figure 5.1) is a 
common damage event in both DNA and RNA, and certain alkylating agents 
accelerate the depurination event, thus contributing to their anticancer activity 
(209). The ribosome-inactivating protein (RIP) is well known to inactivate 
ribosomes by cleaving the glycosidic bond of a single adenosine in the large 
subunit rRNA (210, 211). This A residue (A4324 in rat) lies within the α-sarcin 
loop, which is conserved in the large subunit rRNAs from bacteria to humans 
(211). In a theoretical study published by the Lippard group, the effect of G-N7 
platination by cisplatin on the depurination reaction was evaluated, and results 
indicated that G-N7 platination has only a minor effect on the stability of 
glycosidic bond (212). Due to cisplatin's preferred reactivity for G, the A 
products have not evaluated. The effects of different coordination products 
have not been examined either. In the work reported in this chapter, we used 
glycosidic survival yield analysis to evaluate the platination effect on the 
stability of purine nucleosides. Survival yield analysis is a routine method in 
mass spectroscopy to assess precursor ion stability (213, 214). Since the 
internal energy of the ion is dependent on its chemical composition, the 
survival yield is also related to the chemical structure (214).  
In addition, aiming at atomic level characterization, infrared multiphoton 
dissociation spectroscopy (IRMPD) was applied to each of the monofunctional 
2a-nucleoside adducts assigned in Chapters 3 and 4 (5a, 5b and 7). IRMPD is 
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similar to traditional infrared spectroscopy, but with significantly improved 
sensitivity (APPENDIX). The obtained IRMPD spectra are compared to results 
from density function theory (DFT) calculations in order to make structural 
correlations with the IR bands (discussed further in Chapter 6) 
 
5.3 Materials and methods 
5.3.1 General 
All chemicals and reagents were purchased from Sigma-Aldrich or Fisher, 
unless otherwise stated. RNase-free, distilled, deionized ddH2O (Millipore 
water) was used for all experiments.  
 
5.3.2 Sample preparation 
The Oplatin (2) samples were prepared as described in Section 2.3.2. The 
monofunctional 2a-nucleoside adducts (5a, 5b, and 7) were isolated as 
described in Section 4.3.2.  
 
5.3.3 FT-ICR mass spectrometry 
Data collection was done by Dr. Zhihua Yang in Dr. M. T. Rodgers' 
laboratory. All of the samples were dissolved in a 50:50 methanol:water 
mixture to a final concentration between 10 and 20 μM. The MS and MS/MS 
analyses were performed on a 7T Bruker SolariX Fourier Transform Ion 
Cyclotron Resonance Mass Spectrometer (FT-ICR, Bruker Daltonics, Bremen, 
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Germany) (APPENDIX). The mass spectra of compound 2 were obtained in 
the negative-ionization mode; the others (5a, 5b and 7) were obtained in the 
positive-ionization mode. Direct infusion ESI experiments were performed at 
an infusion rate of 2 µL/min. The nebulizing (NZ) drying gas temperature was 
set at 180 °C with a flow rate of 4 L/min and held at 1.2 bar. The ESI capillary 
voltage was set between 3.5 and 4.5 kV for 2, and between -3.5 and -4.5 kV 
for 5a, 5b and 7. The capillary exit was typically held at 120 V with the deflector 
plate set at 140 V. Ion funnel 1 was operated at 90 V, with skimmer 1 at 20 V. 
The number of ions to fill the instrument for each acquisition was set at 108 to 
avoid space charge effects. The trapping potentials of the FT-ICR analyzer 
were set at 0.8 V, and the analyzer entrance was maintained at 7 V. The side 
kick was set at −4.0 V for 2 with a side kick offset of −4.5 V, or it was set at 4.0 
V with a side kick offset of 4.5 V for 5a, 5b and 7 to further optimize peak 
shape and signal intensity. 
 
5.3.4 Glycosidic bond survival yield analysis 
Data collection was done by Dr. Zhihua Yang and Chenchen He in Dr. M. T. 
Rodgers' laboratory. Glycosidic bond survival yield analysis was performed 
using a Bruker amaZon ETD quadrupole ion trap mass spectrometer 
(APPENDIX) (Bruker Daltonics, Bremen, Germany). The protonated 
2a-nucleoside adducts (5a, 5b, and 7) were generated by an Apollo 
electrospray ionization (ESI) source from solutions of 0.01 mM sample 
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dissolved in a 50:50 methanol:water mixture. All solutions were infused at a 
flow rate of 3 μL/min using a Hamiltonian syringe connected to the Apollo ESI 
source. These liquid samples were introduced through the nebulizer assembly 
into the spray chamber at a temperature of 200 °C and a pressure of 0.69 bar. 
N2 was used as the heated drying gas flowing countercurrent to the stream of 
droplets at a flow rate of 3.0 L/min to aid volatilization, ionization, and carry 
away any uncharged material. Protonated monofunctional adducts (5a, 5b and 
7) were formed and focused directly into the entrance of the glass capillary. 
The capillary voltage was held at 4.5 kV to transfer ions into a dual ion funnel. 
Helium gas was introduced into the ion trap as the collision gas. The pressure 
of the collision gas was about 1 mTorr. The primary rf amplitude was applied to 
the ring electrode for trapping ions. An auxiliary dipolar amplitude was applied 
to the second end-cap electrode for exciting ions. The qz value was set to 0.25 
for ion trapping. The rf excitation amplitude was varied from 0.00 at 0.01 V step 
sizes until complete fragmentation of the precursor ion was observed. The 
isolation window for the precursor ions was of 0.8 m/z width. Spectra were 
recorded in the positive-ion mode for protonated Oplatin-nucleoside adducts. 
Each data point was an average of three repeats. Data analysis was 
performed using Compass Data Analysis 4.0.  
Glycosidic bond survival yield curves were deduced based on the signal 
intensity and Equation 5.1, in which P is the precursor ion, and F is the 
fragment ion. 
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Equation 5.1 
 
5.3.5 IRMPD analysis 
IRMPD action spectra of Oplatin-nucleoside adducts were obtained using 
a laboratory-constructed 4.7 T Fourier transform ion cyclotron resonance mass 
spectrometer (Cryomagnetics, Inc., Oak Ridge, TN) with a 128 mm i.d. 
horizontal bore (215). Photodissociation is induced by the widely tunable free 
electron laser for infrared experiments (FELIX) (APPENDIX) (215-217). A final 
sample concentration of 0.5 mM in a 50:50 MeOH:H2O solution was used. The 
solutions were delivered to a Micromass "Z-spray" electrospray ionization (ESI) 
source at a flow rate between 2.5 and 8.5 μL/min. The ions emanating from the 
spray were accumulated in an rf hexapole ion trap for several seconds prior to 
pulsed extraction through a quadrupole deflector. The precursor ions were 
injected into the FT-ICR MS via a 1 meter-long rf octopole ion guide, and 
stored in the ICR cell to cool to room temperature by radiative emission. FELIX 
typically produces high-energy (50-100 mJ) macropulses of 1-ns-spaced 
micropulses for a duration of about 5-10 μs. The monofunctional adducts (5a, 
5b, and 7) were isolated using stored waveform inverse Fourier transform 
(SWIFT) techniques and irradiated for 3 s corresponding to interaction with 15 
macropulses from the free electron laser to induce IR photodissociation over 
the wavelength range between ~16.0 μm (~625 cm-1)  and ~5.2 μm (~1920 
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cm-1). The IRMPD yield was determined based on Equation 5.2, and then 
normalized linearly with laser power to correct for changes in the laser power 
as a function of photon energy.  
   Equation 5.2 
 
5.4 Results and discussion 
5.4.1 CID studies of Oplatin (2) 
In order to evaluate platination-effects on the glycosidic bond strength of 
nucleosides, and further explore the potential of MS/MS in Pt(II)-RNA related 
studies, the fragmentation patterns of Oplatin (2) and its reaction products with 
adenosine were analyzed. Using the procedure described in Section 5.3.2, 2 
was analyzed first using MS in the negative-ion mode. The anticipated 396.0 
m/z ion was isolated and the collision voltage was applied further to cause 
fragmentation of 2 (Figure 5.2).  
 
Figure 5.2. CID results of Oplatin (396.0 m/z in negative-ion mode) under low collision 
voltage are given. The precursor ion is marked with asterisk. 
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Figure 5.3. A comparison of experimental and simulated spectra of Oplatin (2) 
fragments is given. 
In CID analysis of 2, three major fragment ions were observed. The 
proposed chemical compositions of those fragments were compared with the 
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simulated spectra for further confirmation (Figure 5.3). Those product ions 
were formed by losing NH3, HCl and (NH3 + HCl) from 2 (Figures 5.2 and 5.3, 
obsd. m/Z: 379.0, 360.0 and 343.0, respectively). 
Figure 5.4. Possible mechanisms of 2 fragmentation are shown. 
 
Based on the structure of 2 and previous literature (218, 219), we 
hypothesized that the increased overall internal energy of 2 due to collisions in 
the cell promotes increased flexibility of the ornithine side chain, and the lone 
electron pair on the side-chain amine group acts as a nucleophile and attacks 
the α-carbon, which further leads to rearrangement and fragmentation as 
shown in Figure 5.4. This result was used as a control in the MS/MS analysis 
on the fragmentation patterns of 2a-nucleoside adducts 
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5.4.2 CID studies and glycosidic bond stabilities of 2a-nucleoside 
adducts (5a, 5b and 7) 
As described in Section 5.2, the effect of platination on the glycosidic bond 
stability has been one focus of cisplatin-nucleoside research (203). Guanosine 
is the primary target site of cisplatin. As a result, the glycosidic bond strength of 
A-cisplatin adducts have not been evaluated, and the relative stabilities of 
different coordination products have not been compared. To evaluate the 
differences in glycosidic bond stabilities between the various monofunctional 
2a adducts, 5a, 5b, and 7, CID-MS/MS was employed. Glycosidic bond 
survival yields were determined for each adduct (Figures 5.5 and 5.7).  
In this part of the project, we compared adducts 5a and 5b, since they 
have the same chemical composition. Two groups of fragments were observed 
in each CID mass spectrum (Figure 5.5), and all of the positive ions showed a 
Pt isotope distribution. The first group contained the fragments formed by 
losing neutral molecules of NH3, HCl, and (NH3 + HCl) from 2a (Figure 5.5 and 
Table 5.1: for 5a, obsd. m/z: 612.1, 593.1, and 576.1, respectively; for 5b, 
obsd. m/z: 612.1, 593.1, and 576.1, respectively); the second group contained 
the fragments corresponding to all of the first group of positive ions 
sequentially losing a ribose sugar (Figure 5.5 and Table 5.1: for 5a, obsd. m/z: 
497.1, 480.0, 461.1 and 444.1; for 5b, obsd. m/z: 497.1, 480.0, 461.1 and 
444.1). 
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Figure 5.5. CID results of 5a and 5b (629.1 m/z in positive-ion mode) under low collision 
voltage are shown. The precursor ion is marked with an asterisk. 
Table 5.1. Detailed assignments of the CID results of 5a and 5b (both are 
[PtCl(Ado)(Orn)]+) 
(Orn = ornithine; Ado = adenosine) 
As described in Section 5.2, depurination is a common form of damage to 
RNA and can contribute to the anticancer activity of certain alkylating drugs 
(209). The glycosidic bond survival yield curves were then determined by 
fragmentation of 5a and 5b from 0.0 V (rf excitation voltage) until the parent ion 
was no longer detectable. The glycosidic bond survival yield curves were then 
deduced based on the signal intensity and Equation 5.1. The survival yield 
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curves were quite different for 5a and 5b (Figure 5.6A); 5a 
([PtCl(Orn)(N1-Ado)]+) demonstrated a higher glycosidic bond stability 
compared to 5b ([PtCl(Orn)(N7-Ado)]+). When higher excitation voltage was 
applied, 5a underwent fragmentations that did not involve breaking the 
glycosidic bond (Figure 5.6B). 
 
Figure 5.6. The glycosidic bond survival yield (A) and individual fragment abundance 
percentage (B) were deduced from the MS/MS data of 5a and 5b by increasing the rf 
excitation valtage from 0.0 V until the parent ion was no longer detectable. (A) The 
glycosidic bond survival yield was determined by using Equation 5.1, and plotted 
versus the excitation voltage applied. (B) The signal intensities of individual fragment 
ions were plotted versus the excitation voltage. 
In order to further compare N7-platination effects on the glycosidic bond 
stability of A and G, a CID mass spectrum of 7 (G-N7 platination) was obtained. 
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Two groups of fragments were observed (Figure 5.7). Similar to the results of 
5a and 5b, the first group contained the fragments formed by losing neutral 
molecules of NH3, HCl, and (NH3 + HCl) from 7 (Figure 5.7 and Table 5.2: m/z: 
628.1, 609.1, and 592.1, respectively); the second group contained the 
fragments corresponding to each of the first group of positive ions sequentially 
losing a ribose sugar (Figure 5.9 and Table 5.2: obsd. m/z: 513.0, 496.0, 
477.1 and 460.0, respectively). 
 
Figure 5.7. CID result of 7 (645.1 m/z in positive-ion mode) under low collision voltage is 
shown. The precursor ion is marked with an asterisk. 
 
 
Table 5.2. Detailed assignments of the CID results of 7 
 
(Orn = ornithine; Guo = guanosine) 
124 
 
 
 
Figure 5.8. The glycosidic bond survival yield (A) and individual fragment abundance 
percentage (B) are deduced from the MS/MS data of 7 by increasing the rf excitation 
valtage from 0.0 V until the parent ion was no longer detectable. (A) The glycosidic 
bond survival yield was determined by using Equation 5.1, and plotted versus the 
excitation voltage applied. (B) The signal intensities of individual fragment ions were 
plotted versus the excitation voltage. 
The glycosidic bond survival yield of 7 ([PtCl(N7-Guo)(Orn)]+) was also 
deduced as mentioned above, and the obtained curve (Figure 5.8) was similar 
to that of 5b (Figure 5.6A). Product 7 underwent fragmentation that did involve 
breaking the glycosidic bond when higher excitation voltage was applied 
(Figure 5.8B) 
 
5.4.3 IRMPD analysis of 5a, 5b and 7 
Aiming at atomic-level characterization of the 2a-nucleoside products and 
a further understanding for the previously mentioned glycosidic bond stability 
differences, infrared multiphoton dissociation (IRMPD) spectroscopy was 
applied to each monofunctional product, 5a, 5b, and 7. Similar to the traditional 
infrared spectroscopy (IR), precursor ions in the ICR cell can absorb photons 
of a certain wavelength (220). This absorption results in a build-up of internal 
energy and cause precursor ion dissociation (220). By plotting the extent of ion 
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dissociation versus wavelength, the IRMPD spectra of the three 
monofunctional adducts, 5a, 5b, and 7, were obtained and are shown in 
Figure 5.9 (220). When the IRMPD data was collected for 5a, the 
[Pt(N1-Ado)(NH3)(Orn)]+ signal was isolated as a precursor ion instead of 5a 
([PtCl(N1-Ado)(Orn)]+) due to its dominant intensity. Since the products are 
isolated by using HPLC with 40 mM ammonium acetate buffer, 5b could further 
react with ammoniun buffer during product isolation, leading to replacement of 
the chlorido ligand by an ammonia. The IRMPD data were later used as an 
experimental standard and directly compared to the results from density 
function theory (DFT) calculations, which will be discussed in Chapter 6. 
 
Figure 5.9. IRMPD spectra of [Pt(N1-Ado)(NH3)(Orn)]+, 5b, and 7, are given. 
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5.5 Conclusions 
In the work discribed in this chapter, we applied tandem mass 
spectrometry and survival yield analysis to obtain stability information on 
monofunctional 2a-nucleoside products. By direct comparison of 5a and 5b, 
we discovered that 5a ([PtCl(N1-Ado)(Orn)]+) has higher glycosidic bond 
strength than 5b ([PtCl(N7-Ado)(Orn)]+). These results reveal for the first time 
that different platinum coordination sites on the nucleoside have different 
effects on glycosidic bond stability. In the future, this information can be utilized 
as a reference for identification of platinum coordination sites by tandem mass 
spectrometry. This work illustrates the potential of MS/MS in RNA-Pt or other 
modification studies to provide stability information on RNA adducts. Other 
tandem mass spectrometry techniques such as infrared multiphoton 
dissociation (IRMPD) were also applied, and the IRMPD spectra of 
2a-nucleoside adducts were obtained. The combination of these experiments 
with computational studies (Chapter 6) will provide a more precise view of 
2a-nucleoside adduct structures, as well as an explanation for glycosidic bond 
stability differences. 
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CHAPTER 6 
Gaussian calculations of Oplatin-nucleoside products* 
 
* This work was carried out in collaboration with Chenchen He and Dr. M.T. 
Rodgers. 
 
6.1 Abstract 
Tandem mass spectrometry was used to obtain an atomic-level 
understanding of the product profiles of monoaquated Oplatin (2a) with 
adenosine (Ado) and guanosine (Guo). For further structural characterization 
of these products, infrared multiple photon dissociation (IRMPD) spectra of the 
electrospray ionization (ESI)-generated monofunctional 2a-nucleoside adducts 
([Pt(N1-Ado)(NH3)(Orn)]+, 5b and 7) were obtained. These results were 
compared to density functional theory (DFT) calculations in order to make 
peak assignments. From the calculation results, we observed that 
2a-nucleoside adducts had the potential to adopt various orientations with 
unique hydrogen bonds between the amino acid ligand and either the 
nucleobase functional groups or the sugar moiety. 
 
6.2 Introduction 
During the last few decades, extensive research has been carried out to 
establish the structure-activity relationships of cisplatin. Computational 
methods have made valuable contributions to our understanding of how 
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cisplatin reacts with DNA (185, 212, 221-224). With atomic-level theoretical 
studies, Lippard's group rationalized cisplatin's G-N7 preference and the 
impact on glycosidic bond strength (185, 212). These findings have 
fundamental importance for the future design of new drugs, and also play an 
important role in this Ph.D. project. With a deeper understanding of the 
cisplatin mechanism of action, issues related to drug resistance and 
dose-related side effects can be addressed. Thousands of cisplatin analogues 
have been synthesized and screened for improved biological activity, but only 
a few have been successful (184, 225-228). Rational drug design is difficult if 
structure-activity relationships are not clear. Therefore, geometries, electronic 
structures, and energy profiles of the Pt(II) complexes and their corresponding 
platination products are important molecular features that need to be 
evaluated theoretically in order to establish such relationships.  
As a summary of the previous chapters, several amino-acid-linked 
cisplatin derivatives were synthesized. Among them, Oplatin (2) demonstrated 
an unambiguous coordination preference for adenosine and single-stranded 
regions of RNA, which makes it the first reported Pt(II) complex with a 
template-independent adenosine preference when reacting with RNA. Further 
product characterization shed light on the mechanisms behind the different 
selectivity of 2, compared to the parental compound cisplatin, such as its ability 
to form a hydrogen bond with the 6-amine group of adenosine. Tandem mass 
spectrometry analysis revealed that coordination of Oplatin (2) to different sites 
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on adenosine (e.g., N1 and N7) affects glycosidic bond stability differently. An 
explanation for this difference is still needed. Based on previous reports on 
cisplatin (176, 203, 214-217), computational methods are considered a reliable 
approach to understanding the mechanism behind the glycosidic bond 
cleavage of products 5a and 5b. 
The core of cisplatin and its derivatives, the Pt(II) metal center, creates a 
challenge in theoretical analyses. This problem arises from the 
incompleteness of the basis set for the third-row transition metals (222-225). 
To overcome this limitation, previous published calculations on cisplatin were 
done with a suitable valence basis set in combination with an effective core 
potential (ECP) for the Pt(II) center (222-225). There are reports on basis set 
evaluation of the prediction accuracy on Pt(II)-containing complex structures, 
electronic properties, and IR spectra (229-232). In 1998, Pavankumar and 
Hausheer et al. compared two different ECPs, referred to as SBK and 
LANL2DZ, and over 30 different basis sets, including 3-21G(d), 6-311*G(3d, 
3pd), and cc-pVDZ, for predicting the chemical structure and IR spectrum of 
cisplatin (229). Based on their performance, two hybrid basis sets (HF 
(Hartree-Fock)/6-311G* and MP2 (Moller-Presset 2nd order perturbation 
theory)/6-311G*) were chosen to describe the molecular properties of cisplatin 
(229). Later in 2007, similar work was reported by Amado, Carvalho and 
coworkers (230). Several methods (e.g., HF, MP and DFT) were evaluated and 
reviewed for their roles in prediction of conformational and vibrational modes of 
130 
 
 
cisplatin (230). Based on the overall results of both prediction accuracy and 
computational demand, and by comparing the results with existing 
experimental data such as X-ray crystal structures, the best result was 
achieved by using the DFT mPW1PW approach coupled to the 6-31G(d) basis 
set for the ligands and the relativistic ECP LANL2DZ for the Pt center (230). 
This basis set was shown to provide the most accurate predicted structure and 
IR spectrum of cisplatin regardless of the theoretical methods (230). More 
recently, Jorge, Berrêdo, and coworkers constructed three all-electron basis 
sets (ABS) on Pt(II)-containing compounds: double zeta valence plus 
polarization function (DZP), augmented double zeta (ADZP, augmented 
nonrelativistic), and DZP-DKH (Douglas-Kroll-Hess) (231, 232). After testing 
the three ABS with the one-parameter hybrid functional mPW1PW on cisplatin 
and carboplatin, they concluded that the ABS are only slightly superior to the 
standard ECP in geometry calculation (231, 232).  
In addition to the lack of conclusive results mentioned above, another 
challenge in our project is that the amino-acid-linked cisplatin analogues have 
an asymmetric configuration that is different from cisplatin and most of its 
derivatives. The summarized publications discussed above are based on the 
structural properties of cisplatin (or carboplatin), which has a symmetric and 
rigid square-planar configuration, and therefore it is possible that the above Pt 
complex calculations are not sensitive to the basis set changes (222-225). 
Furthermore, the evaluated basis sets are not yet validated with other 
131 
 
 
derivatives, especially ones with distinct reactivity from cisplatin. As a result, in 
order to obtain reliable predictions on the structure and energy profiles of 
2a-nucleoside adducts (5a, 5b, and 7), evaluations of the different basis sets, 
as well as stepwise structure optimizations will be important. 
 
6.3 Methods  
All calculations presented here were carried out using the density 
functional theory, as implemented in the Gaussian-09 set of programs (233, 
234). Geometries were optimized by using the B3LYP functional with the 
def2-TZVPPD basis set, without any symmetry constraints (186). Platinum 
was represented by the defz-TZVPPD basis set, which includes relativistic 
effective core potentials (186). The energies were re-evaluated by additional 
single point calculations at each optimized geometry using the B3LYP 
functional with the def2-TZVPPD basis set (186). In these single-point 
calculations, Pt was also described by the defz-TZVPPD basis set (186). 
 
6.4 Results and discussion 
6.4.1 Basis set evaluation  
Since this is a collaborative project, two directions were carried out at the 
same time, one focused on choosing the best basis set in describing the 
asymmetric Pt(II) complex system (done by Chenchen He), and the other 
involving geometry optimization of the Pt(II) complexes (1 and 2) and its 
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corresponding nucleoside adducts (5a, 5b, and 7). Chenchen He in Dr. 
Rodger's group focused on basis set evaluation by using Gplatin (1) as a 
model study. For comparison, the IRMPD action spectrum of 1 was obtained 
and used to verify the reliability of the calculations. First, all of the possible 
structures of Gplatin were projected into the calculations. Then, by comparing 
the calculated spectra with the IRMPD spectra, and their energy profiles, some 
structures were ruled out. Lastly, three different levels of theory and basis sets 
were tested, including different ECPs and four ABS (this part of the work was 
done by Chenchen He). Gplatin (1) has an asymmetric structure (Chapter 2), 
and has preference for A over G nucleosides (Chapter 3). Basis set evaluation 
by using 1 as a standard helped us choose the most suitable basis set for 
describing amino-acid-linked Pt(II) complexes such as Oplatin (2) 
 
6.4.2 Further examination of the coordination mode of glycine to Pt(II)  
The second part of this work was done together with Chenchen He 
(Rodgers' Laboratory), and started with structure optimization of 1. The hybrid 
basis set mentioned in Section 6.3 was used in the calculations. Glycine has 
three atoms available for metal coordination, two oxygen atoms from the 
carboxylate group and one nitrogen atom in the α-amine group (Figure 6.1).  
Based on the reported X-ray crystal structures of Oplatin (2) and Kplatin, 
the Pt(II) center is coordinated to one of the carboxylate oxygen atoms and the 
α-amine nitrogen atom (158-160). The structure centered around the Pt(II) 
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metal center was square planar (158-160). Since the IRMPD data were 
obtained in the gas phase, we took extra precautions to confirm the structure 
that was based on X-ray data. We used the published structure of cisplatin 
coordinated to G-N7 as a starting point, and the coordination modes and sites 
were varied while maintaining a square-planar configuration around the metal 
center. Different initial structures were proposed and calculated at the 
def2-TZVPPD level, and the results are summarized in Figure 6.2. The 
relative energy profiles are provided as a reference and expressed in kJ/mol.  
 
Figure 6.1. The chemical structure of glycine is shown. The oxygen and nitrogen 
atoms that are available for metal coordination are highlighted in red.  
 
NH2-Pt-G_N7_Gplatin_1 was identified as the optimized structure with the 
lowest energy profile. In this structure, Gplatin (1) still maintained a 
square-planar configuration and G-N7 was trans with respect to the α-amine 
group. Glycine coordinates to Pt(II) through the α-amine nitrogen and one of 
the carboxylate oxygen atoms. This arrangement is consistent with the 
literature (158-160) and the proposed structure (Chapter 2). Due to the 
asymmetry of Gplatin (1), another structure, OCO-Pt-G_N7_Gplatin_1 (G-N7 
is trans with respect to the carboxylate group) was also obtained with a slightly 
higher energy value (8.3 kJ/mol) than NH2-Pt-G_N7_Gplatin_1. In 
OCO-Pt-G_N7_Gplatin_1, the structure of 1 is the same as that in  
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Figure 6.2. Geometries and relative free energies (kJ/mol, in parenthesis, in italics) 
of [PtCl(Gly)(N7-Gua)] (Gua = guanine) were calculated at the def2-TZVPPD level 
with various initial Gplatin (1) structures. All of the unlabeled atoms are hydrogen. 
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NH2-Pt-G_N7_Gplatin_1, and a potential hydrogen bond was observed 
between the α-amine and G-O6. Calculations resulted in different Gplatin 
structures (e.g., in both structures OCO-Pt-G_N7_Gplatin_2 and 
OCO-Pt-G_N7_Gplatin_3) glycine coordinates to Pt(II) through two 
carboxylate oxygen atoms) were also obtained; however, the energy values of 
those structures are significantly higher than that of NH2-Pt-G_N7_Gplatin_1 
(68.3 kJ/mol and 67.5 kJ/mol, respectively). Based on the calculation results 
discussed above, the structure of 1 in [PtCl(Gly)(N7-Gua)] is optimal, which is 
consistent with the data presented in Section 2.3. The two structures, 
NH2-Pt-G_N7_Gplatin_1 and OCO-Pt-G_N7_Gplatin_1, were used later as 
the starting point in the next step of structural optimization. 
 
6.4.3 Comparison of monohydrated Oplatin (cis- and trans-2a) 
structures 
Due to the asymmetry of 2, monoaquation of Oplatin can theoretically yield 
two activated forms, cis- and trans-2a (Figure 6.3). Based on the kinetic trans 
effect (193-195) discussed in Section 4.3, we concluded that the 
monoaquation of Oplatin (2) would yield one activated form, cis-2a. Here, in 
this section, further calculations were done on both cis- and trans-2a, and their 
energy profiles were compared. 
The results of these computations (Figure 6.4) further confirmed our 
conclusion (Section 4.3) that monoaquation of 2 yields the activated form 
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cis-2a. When cis-2a further reacts with RNA or nucleosides, a hydrogen bond 
could potentially form with adenosine 6-amine group when binding at the A-N1 
or N7 position. This stabilizing factor was proposed predominantly to its 
template-independent adenosine selectivity. 
 
Figure 6.3. The reaction scheme of Oplatin monoaquation and the two possible 
monoaquated Oplatin structures are shown. 
 
Figure 6.4. Geometries and relative energies (kJ/mol, in parentheses, in italics) of 
cis- and trans-2a were calculated at the def2-TZVPPD level. All of the unlabeled 
atoms are hydrogen. 
 
6.4.4 Structure optimization on possible 1a-nucleoside adducts 
After optimizing the structures of 1 and cis-2a, the structures of possible 
1a-nucleobase adducts were also evaluated, and their energy profiles were 
compared for further calculation. Besides the reported common platination 
sites, A-N1, A-N7 and G-N7, the A-N3, G-N3, and G-O6 positions were also 
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taken into consideration. For each binding site, both cis- and trans-2a (Figure 
6.4) were used in the initial structure constructions. The overall optimized 
structures and corresponding energy profiles are summarized in Figure 6.5 
and 6.6. The optimized structures were further utilized in the next step of 
calculation on the Gplatin-nucleoside adducts. 
As summarized in Figure 6.5, the two NH2-Pt-A-N3 structures 
(NH2-Pt-A-N3_1 and NH2-Pt-A-N3_2) are the most stable adducts with the 
lowest energy values (0.0 kJ/mol and 9.1 kJ/mol, respectively); however, this 
situation was expected to change in the next step of calculation with the 
nucleoside. With the addition of a ribose sugar at the N9 position of adenine, 
steric factors will occur and further destabilize N3-platination. In addition, 
elimination of the hydrogen bond between the chlorido ligand or carboxylate 
group in Gplatin (1) with A-H9 will disfavor N3-platinated adducts. Besides the 
N3-platination adducts, it is also worth noting that when adenine is trans with 
respect to the α-amine, the overall energy profile is significantly lower than 
those adducts in the cis configuration (comparing the energy values of 
NH2-Pt-A-N1_1, NH2-Pt-A-N1_2 with OCO-Pt-A-N1, or NH2-Pt-A-N7_1, 
NH2-Pt-A-N7_2 with OCO-Pt-A-N7_1 and OCO-Pt-A-N7_2). When comparing 
N1 and N7 platination, the energy difference of the optimized structures is 
negligible, which is also consistent with the HPLC data in Section 3.4.3, in 
which no preference was observed in peak intensities and increasing 
formation rates of the two fractions (A1 and A2).   
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Figure 6.5. Geometries and relative energies (kJ/mol, in parentheses, in italics) of 
[PtCl(Gly)(N1-Ade)]+, [PtCl(Gly)(N3-Ade)]+, and [PtCl(Gly)(N7-Ade)]+ (Ade = adenine) 
were calculated at the def2-TZVPPD level. All of the unlabeled atoms are hydrogen. 
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Figure 6.6. Geometries and relative energies (kJ/mol, in parentheses, in italics) of 
[PtCl(Gly)(N3-Gua)]+, [PtCl(Gly)(O6-Gua)]+ and [PtCl(Gly)(N7-Gua)]+ (Gua = guanine) 
were calculated at the def2-TZVPPD level. All of the unlabeled atoms are hydrogen. 
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Similar to the 1-adenine results (Figure 6.5), platination at the G-N3 
position also yielded the structures with the lowest energy profiles (Figure 6.6) 
among all of the possible monofunctional 1-guanine adducts. This scenario 
also changed after addition of the ribose sugar at the G-N9 position due to the 
introduction of steric factors and elimination of the hydrogen bond. Besides the 
G-N3 adducts, the most stable structure was NH2-Pt-G-N7. In this structure, 
platination occurred at the guanine N7 position, which was consistent with the 
observed experimental data presented in Section 4.4.1.2. Guanine and the 
α-amine group are in a trans configuration. In contrast to the optimized 2-A-N7 
structures (Figure 6.5), no hydrogen bond was observed between the Pt(II) 
complex and guanine. Instead, a 3.3 Å distance occurred in order to minimize 
the possible repulsive interaction between the negatively charged oxygen 
atom in 1 and G-O6. This result further supports the proposed product profiles 
and mechanism of A (Ado) preference as mentioned in Section 4.5. The 
optimized structures (Figure 6.5 and 6.6), with platination occurring at A-N1, 
A-N7 or G-N7 were utilized in further calculations on the 2a-nucleoside 
adducts. 
 
6.4.5 Structure optimization and IR spectrum computation on 
[Pt(N1-Ado)(NH3)(Orn)]+ (Ado = adenosine) 
Aiming at an atomic-level understanding of both the structure and energy 
aspects of 2a-nucleoside adducts, IRMPD action spectroscopy was applied in 
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Chapter 5, and the "IR" spectra were obtained as guides to finalize the DFT 
calculations. To compute the energy profiles of 5a, 5b, and 7, it was first 
necessary to assemble the structures. The optimized structures in the last two 
sections (Sections 6.4.3 and 6.4.4) were used as a base to further build the 
final adducts. As summarized in Section 4.3, the three major monofunctional 
adducts between 2a and nucleosides were A-N1, A-N7, and G-N7 
monofunctional adducts. In this and the next few sections, the ribose sugar 
and ornithine side chain were then added stepwise onto the optimized 
Gplatin-AN1, Gplatin-AN7 and Gplatin-GN7 structures. The IR spectra of all 
the structures were also computated and compared with the experimental 
data.  
After adding the ribose sugar, the structures of [PtCl(Gly)(N1-Ado)]+ (Ado = 
adenosine) were calculated and the results are summarized in Figure 6.7. The 
ribose sugar adopted a C3'-endo conformation with the 5'-hydroxyl group in 
relatively close distance to the A-H8 (~3.2 Å). Two different types of hydrogen 
bonds were present in structures of 1 coordinated to adenosine. One type was 
between the chlorido ligand and the adenosine 6-amine (Gplatin-A-N1_1, 
Gplatin-A-N1_2, Gplatin-A-N1_5 and Gplatin-A-N1_6), and the other type was 
between the carboxylate group and adenosine 6-amine (Gplatin-A-N1_3 and 
Gplatin-A-N1_4). The latter showed a better stabilizing effect with a relatively 
shorter hydrogen bond (1.8 and 1.9 Å instead of 2.3 Å). As a result, the 
structures Gplatin-A-N1_3 and Gplatin-A-N1_4 were most thermodynamically 
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stable at this step.  
 
 
Figure 6.7. Geometries and relative energies (kJ/mol, in parentheses) of 
[PtCl(Gly)(N1-Ado)]+ (Ado = adenosine) were calculated at the def2-TZVPPD level. 
All of the unlabeled atoms are hydrogen. 
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As a final step, the side chain of ornithine was added to the structures. 
Another thing worth mentioning is that when the IRMPD data (for the A-N1 
monofunctional adduct) were collected, the [Pt(N1-Ado)(NH3)(Orn)]+ signal 
was isolated as a precursor ion instead of [PtCl(N1-Ado)(Orn)]+ due to its 
dominant intensity. Therefore, the Cl ligand was replaced by NH3 in order to 
make the structure composition consistent with the experimental data. The 
theoretical IR spectra of the computed structures (Figure 6.8) were compared 
with the experimental IRMPD data (Figure 6.9). 
After the final addition of the ornithine side chain and adjustment, the 
optimized geometries of [Pt(NH3)(N1-Ado)(Orn)]+ were obtained and are 
summarized in Figure 6.8. The ribose sugar still adopted a C3'-endo 
conformation; however, the side-chain orientation varied. For example, in the 
structures, Oplatin-A-N1_1, Oplatin-A-N1_4 and Oplatin-A-N1_5, the side 
chain amine was unbound and did not interact with either Pt(II)-five-member 
ring or adenosine. On the other hand, the side chain of ornithine folded back 
and close to the α-amine in the Oplatin-A-N1_2 and Oplatin-A-N1_6 structures. 
Even though the possible hydrogen-bonding interaction between two amine 
groups could provide certain stabilizing effects, tension in the folded side chain 
also contributed additional destabilization and resulted in a slightly less stable 
energy value. Among the finalized structures, the Oplatin-A-N1_5 was the 
most stable; however, in this structure, A-N1 was cis with respect to the 
α-amine ligand. As suggested by our previous data (Section 6.4.3), the  
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Figure 6.8. Geometries and relative energies (kJ/mol, in parentheses, in italics) of 
[Pt(N1-Ado)(NH3)(Orn)]+ (Ado = adenosine) were calculated at the def2-TZVPPD level. 
All of the unlabeled atoms are hydrogen. 
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Figure 6.9. A comparison of experimental IRMPD data (black, top) with the predicted 
IR spectra (with 0.98 scaling factor) of the optimized [Pt(N1-Ado)(NH3)(Orn)]+ (Ado = 
adenosine) structures is given. The experimental data are also overlayed (grey) onto 
each of the computed spectra. 
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monoaquation of Oplatin yielded the activated form cis-2a, and this activation 
step was complete before reacting with the nucleoside. Therefore, the best 
representatives for the adduct [Pt(N1-Ado)(NH3)(Orn)]+ were expected to be 
Oplatin-A-N1_1 and Oplatin-A-N1_2, and their computed spectroscopic 
characteristics further confirmed that hypothesis (Figure 6.9).  
The predicted IR spectra (Figure 6.9) showed some agreement with the 
IRMPD data; however, further optimization on the details such as the scaling 
factor is still needed in order to obtain a better match. At this point, the parallel 
project carried out by Chenchen He in Dr. Rodgers' group on the evaluation of 
the basis sets in amino-acid-linked Pt(II) complex calculations provided a 
preliminary conclusion. It is currently believed that the def2-TZVPPD basis set 
is not a very efficient or accurate method for predicting the energy and 
spectroscopic characteristics of these Pt(II) complexes. This deficiency could 
also contribute to the lack of overlap between the predicted and experimental 
IR spectra (Figure 6.9). More information is still needed to choose the best 
basis set for this project. Oplatin-A-N1_1 and Oplatin-A-N1_2 computed IR 
spectra were shown most closely match with experimental IR spectra. 
 
6.4.6 Structure optimization and IR spectrum computation on 
[PtCl(N7-Ado)(Orn)]+ (5b) (Ado = adenosine) 
Similar to Section 6.4.5, the final steps in structure optimization of 
[PtCl(N7-Ado)(Orn)]+ (5b) were continued using the structures shown in 
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Figure 6.5. First, the ribose sugar was added; the results of both structures 
and energy profiles are summarized in Figure 6.10. Similar to the results 
presented in Figure 6.7 and also consistent with our conclusions in Section 
4.3, the most thermodynamically stable configuration of [PtCl(Gly)(N7-Ado)]+ 
was Gplatin-A-N7_1 (Figure 6.10). In this structure, a hydrogen bond formed 
between the oxygen in the carboxylate group and the adenosine 6-amine. In 
addition, another hydrogen bond was formed between the chlorido ligand and 
5'-OH group with the ribose sugar in a C3'-endo conformation. A-N7 is trans 
with respect to the α-amine ligand. All of the above factors contributed to 
stabilization of the overall structure. Another structure, Gplatin-A-N7_2, also 
presented a relatively stable energy profile (1.5 kJ/mol). The only difference 
from the Gplatin-A-N7_1 structure was the hydrogen bonds: two hydrogen 
bonds were involved in this structure, one between the chlorido ligand and the 
6-amine; the other one between the carboxylate group and the 5'-OH. 
Lastly, similar to Section 6.4.5, the side chain of ornithine was added to 
the above structures and calculated. The theoretical IR spectra (Figure 6.12) 
of the final structures (Figure 6.11) were also computed and compared with 
experimental IRMPD data. Based on the structures summarized in Figure 6.11, 
5b appeared to be able to adopt more various orientations than 
[Pt(N1-Ado)(NH3)(Orn)]+. Both monoaquated Oplatin forms (cis- and trans-2a) 
were used in this step of the calculations. The types of electrostatic 
interactions between the Pt(II) center and nucleobase region were divided 
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Figure 6.10. Geometries and relative energies (kJ/mol, in parentheses, in italics) of 
[PtCl(Gly)(N7-Ado)]+ (5b) (Ado = adenosine) were calculated at the def2-TZVPPD 
level. All of the unlabeled atoms are hydrogen. 
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Figure 6.11. Geometries and relative energies (kJ/mol, in parentheses, in italics) of 
[PtCl(N7-Ado)(Orn)]+ (5b) were calculated at the def2-TZVPPD level. All of the 
unlabeled atoms are hydrogen. 
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Figure 6.12. A comparison of experimental IRMPD data (black, top) with the 
computed IR spetra (with 0.98 scaling factor) of [PtCl(N7-Ado)(Orn)]+ (5b) (Ado = 
adenosine) structures is given. The experimental data are also overlayed (grey) onto 
each of the computed spectra. 
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into three types: the first type forms a hydrogen bond between the carboxylate 
group and adenosine 6-amine (Oplatin-A-N7_3, and Oplatin-A-N7_4); the 
second type of hydrogen bond was between the chlorido ligand and 
adenosine6-amine (Oplatin-A-N7_1, Oplatin-A-N7_2, Oplatin-A-N7_5, and 
Oplatin-A-N7_7), and in the last type, the adenosine 6-amine interacted with 
the α-amine group in Oplatin (Oplatin-A-N7_6, Oplatin-A-N7_8, 
Oplatin-A-N7_9, and Oplatin-A-N7_10). The orientations of the side chain 
were categorized into three types as well. In the majority of the above 
structures, the side-chain amine participated in a close electrostatic interaction 
with the five-membered ring moeity of 2 (Oplatin-A-N7_1, Oplatin-A-N7_3, 
Oplatin-A-N7_5, Oplatin-A-N7_7, Oplatin-A-N7_8 and Oplatin-A-N7_10); in 
another group, the ornithine side chain was in an unbound position relatively 
far away from any other functional groups (Oplatin-A-N7_6 and 
Oplatin-A-N7_9); in the last category, which was the most interesting, the side 
chain was folded in a certain conformation which allowed the side chain amine 
to form multiple hydrogen bonds with both the Pt(II)-five-membered-ring center 
and the 5'-OH group in the ribose (Oplatin-A-N7_2 and Oplatin-A-N7_4). 
Further information is still needed to conclude whether this configuration can 
affect glycosidic bond stability. In this round of calculations, the lowest energy 
structures were Oplatin-A-N7_1 and Oplatin-A-N7_3. In both of these 
structures, the side chain amine participated in an electrostatic interaction only 
with the Pt-five-member ring.  
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The computed IR spectra of all the [PtCl(N7-Ado)(Orn)]+ structures are 
shown in Figure 6.12. Due to the current choice of scale factor and basis set, 
consistency between computed IR spectra and experimental IRMPD data is 
not great. After finishing the evaluation of the basis sets, a second computation 
of IR spectra is needed, which would offer improved consistency and further 
information on the structure and energy characteristics of adduct 5b. 
 
6.4.7 Structure optimization and IR spectrum computation on 
[PtCl(N7-Guo)(Orn)]+ (7) (Guo = guanosine) 
Structure optimization was also continued on adduct 7. As in Sections 
6.4.5 and 6.4.6, the ribose sugar was added in the first step. The results on 
both structures and energy profiles are summarized in Figure 6.13. The most 
thermodynamically stable structure among all of the calculated structures 
above (Figure 6.13) was Gplatin-G-N7_1. In this structure, Gplatin 
coordinated to G-N7 trans with respect to the α-amine. The distance between 
the oxygen in the carboxylate group and G-O6 was over 3 Å. The ribose sugar 
was in a C3'-endo conformation, which was the same as in the Gplatin-A-N7 
structures. The side chain of ornithine was then added (Figure 6.14) and the 
theoretical IR spectra (Figure 6.15) were also computed and compared with 
experimental IRMPD data. The summarized [PtCl(N7-Guo)(Orn)]+ (7) 
structures are shown in Figure 6.14. Several differences were noticed when 
compared to the 5b results. First, only one orientation was observed between  
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Figure 6.13. Geometries and relative energies (kJ/mol, in parentheses, in italics) for 
[PtCl(Gly)(N7-Guo)]+ (Guo = guanosine) were calculated at the def2-TZVPPD level. 
All of the unlabeled atoms are hydrogen. 
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Figure 6.14. Geometries and relative energies (kJ/mol, in parentheses, in italics) for 
[PtCl(N7-Guo)(Orn)]+ (7) (Guo = guanosine) were calculated at the def2-TZVPPD level. 
All of the unlabeled atoms are hydrogen. 
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Figure 6.15. A comparison of experimental IRMPD data (black, top) with the 
computed IR spetra (with 0.98 scaling factor) of [PtCl(N7-Guo)(Orn)]+ (7) (Guo = 
guanosine) structures is given. The experimental data are also overlayed (grey) 
onto each of the computed spectra. 
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the Pt(II)-five-membered ring and nucleobase moiety when cis-2a was used as 
the monoaquated Oplatin form. The distance between the negative-charged 
carboxylate group and the G-O6 was approximately 3.2 Å. The side chain 
amine of Oplatin forms electrostatic interactions with the Pt(II)-five-membered 
ring (Oplatin-G-N7_1, Oplatin-G-N7_3, Oplatin-G-N7_6 and Oplatin-G-N7_8) 
or the 5'-OH in the ribose sugar (Oplatin-G-N7_4 and Oplatin-G-N7_5). In 
addition, one more type of orientation was also observed in the structure 
Oplatin-G-N7_2, in which the side chain amine not only formed a hydrogen 
bond with the carboxylate group near the Pt(II) center, but also interacted with 
G-O6. The most stable structures of 7 were Oplatin-G-N7_1 and 
Oplatin-G-N7_2, in which the side-chain amine of Oplatin formed a hydrogen 
bond with the carboxylate group. 
The computed IR spectra of the above-mentioned structures are shown in 
Figure 6.15. Similar to adduct 5b, the consistency between the computed IR 
spectra and the experimental IRMPD data is lacking. Further evaluation of the 
basis sets and scale factor is definitely important and essential for the 
completion of this project. 
 
6.5 Conclusions and future directions 
In this chapter, a computational study was applied to further obtain an 
atomic-level understanding of the structural, energy, and spectroscopic 
characteristics of 2a-nucleoside adducts, especially 5a, 5b, and 7. In order to 
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achieve this goal, two directions were carried out in parallel. First, due to the 
incompleteness of the basis set design on the third-row transition metals, 
evaluation on the basis set effect on computation accuracy was required to 
choose a suitable method. This part of the project is currently being continued 
by Chenchen He in Dr. Rodgers' group. In the second direction, as a 
collaboration with Chenchen He, we began geometry optimization on the 
Gplatin component of [PtCl(Gly)(N7-Gua)]+, and the results were consistent 
with our data (Chapter 2). Then, the two monoaquated Oplatin forms (cis- and 
trans-2a) were computed and their energy profiles were compared. Product 
cis-2a was determined to be the preferred monoaquated form. This result 
provides further support of our proposed theory on product structures and the 
mechanism for adenosine-preference of 2 (Chapter 4). Next, various possible 
platination sites on both nucleosides, adenosine and guanosine, were 
compared. The A-N1, A-N7, and G-N7 positions were more favored than other 
sites such as G-O6. Lastly, further structure optimization was performed on 
[Pt(N1-Ado)(NH3)(Orn)]+, 5b and 7 by adding the ribose sugar and ornithine 
side chain in a stepwise fashion. The resulting calculated structures were 
summarized, and their IR spectra were computed as well. From the resulting 
structures, we observed that different orientations occur on the ornithine side 
chain. More specifically, the side chain of ornithine has the possibility to 
interact with the nucleoside sugar moeity in adducts 5b and 7; however, due to 
the fact that the current basis set is not the best in describing the Pt(II) 
164 
 
 
complexes, the computed IR spectra did not match very well with the 
experimental IRMPD data. Further work on evaluation of the basis set is 
needed to obtain improved IR computations. In addition, the possibility that an 
interaction between the side chain amine and the ribose sugar causes the 
difference in glycosidic bond stability is still under investigation. 
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CHAPTER 7 
General conclusions and future directions 
 
7.1 General conclusions 
With this multidisciplinary research, we have demonstrated that: 1) altered 
reactivity of cisplatin can be achieved by replacing the carrier ligands with 
different amino acids; 2) Oplatin (2) displays a template-independent kinetic 
preference for adenosine (A) over other nucleosides/nucleotides when 
reacting with RNA; 3) Oplatin forms monofunctional adducts with adenosine at 
the N1 or N7 positions (5a and 5b, respectively), and with guanosine at the N7 
position (7). In addition, the use of tandem mass spectrometry reveals for the 
first time that the different coordination sites of 2a on adenosine can lead to 
different stabilities of the glycosidic bond. The A-N1 adduct (5a) has higher 
glycosidic bond stability than the A-N7 adduct (5b). Lastly, through 
computational calculations and IRMPD studies, we have obtained atomic-level 
details of the adducts, [Pt(N1-Ado)(NH3)(Orn)]+, 5b, and 7. These results not 
only enrich our understanding of structure-activity relationships between 
amino-acid-linked cisplatin analogues and RNA, but also illustrate the potential 
of utilizing various tandem mass spectrometry techniques for future RNA-Pt(II) 
studies. 
 
7.2 Future directions 
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The synthesis of amino-acid-linked platinum complexes is relatively 
forwardstraight. There are multiple choices of amino acids and related ligands 
to use for future studies, including both natural and unnatural amino acids. As 
an example, Gplatin was synthesized to understand the side-chain effect on 
the RNA reactivity of amino-acid-linked Pt(II) complexes. In order to further 
confirm the proposed mechanism of Oplatin (2)'s altered preference, the 
detailed adduct profile and kinetic characterization of 2 with nucleosides is 
certainly helpful without the possible influence from the basic side chain. The 
synthesis of Gplatin is being continued by Bett Kimutai. 
From the coordination studies done in this Ph.D. work, it is clear that 
altered reactivity is observed with carrier ligand modification, so it is possible 
that by expanding the category of synthesized amino-acid-linked cisplatin 
analogues, there is still additional potential to obtain analogues with distinct 
reactivity and altered specificity.  
Ribosomal RNA is a structurally diverse molecule. Its structural dynamics 
are known to be important for both biological function and potential drug 
interactions (235). Previously, Dr. Keshab Rijal successfully developed a 
methodology of using cisplatin to probe rRNA structure in vitro and in vivo; 
however, probes with varying specificity are still needed (119, 236). Compared 
to cisplatin, Oplatin is relatively larger and has a different charge distribution 
(158-160). Its structural characteristics result in an alternative coordination 
behavior with a preference for A over G; it also react exclusively to 
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single-stranded RNA regions. This result not only provides additional 
information on solvent accessibility of RNA, but also gives us the first piece of 
the puzzle regarding how modification affects Pt complex reactivity toward 
RNA. With more amino-acid-linked platinum complexes available, further 
binding and probing studies can be achieved. RNA structure information and 
the structure-activity relationship of Pt(II) complexes with RNA can be further 
obtained and applied to the rational design of RNA-targeting Pt(II) complexes 
or drugs.  
Two recent reports suggest that cisplatin can coordinate quickly and 
accumulate more in RNA than DNA (119, 121). This discovery provides a new 
view with respect to using RNA as an anticancer drug target. As discussed in 
Chapter 1, RNA is located in the cytoplasm, which makes it more accessible 
than DNA. As a result, it has also been hypothesized that if the anticancer drug 
can be modified to be more reactive towards RNA, the dose-related toxicity of 
Pt(II)-based drug could be greatly reduced (119, 121). Also, since RNA repair 
mechanisms are not as systematic as those for DNA, resistance caused by the 
DNA repair system may be avoided. From the data presented in this thesis, 
Oplatin (2) has shown high reactivity in an RNA loop region, which is a unique 
secondary structure in RNA (122). This makes Oplatin (2) a potential Pt-based 
drug lead for targeting RNA.  
Tandem mass spectrometry is a relatively new and powerful technique. 
Based on its application in proteomics and metabolomics studies, it also 
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presents great potential in RNA-related studies. The combination of 
computational calculations with IRMPD studies can provide detailed 
information on the structure, energy, and spectroscopic characteristics of 
RNA-Pt adducts, and this will also be helpful in the interpretation of MS/MS 
data. However, due the immaturity and incompleteness of methodology in this 
area, further work is still needed that focuses on optimizing the experimental 
procedures and computation methods. 
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APPENDIX 
Information in this appendix is the instrumentation introduction for Chapter 5. 
 
 
Figure 1. Diagrams of three beam mass analysers are shown. (A) Time-of-flight (TOF) 
spectrometry analyzes mass-to-charge ratios based on the principle that different m/z 
ions have different velocities and therefore reach the detector at different times. (B) A 
double-focusing mass analyzer analyzes ions based on their different kinetic 
energy-to-charge ratios. Ions with the same kinetic-energy-to-charge value are 
dispersed on the same path. (C) A quadrupole mass analyzer separates ions by 
maintaining stable trajectories of the ions with the same m/z, while the others are 
ejected (205). 
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Based on the different types of mass analyzer, the types of mass 
spectrometers can be divided into two general groups: beam analyzer 
instruments (Figure 1) and trapping analyzer instruments (205). In the beam 
analyzer, ions travel in a beam to the detector (205). In the trapping analyzer, 
ions are trapped in a defined space for separation and detection (205). In this 
section, two major types of trapping instruments are introduced and their mass 
separation and detection mechanism are given.  
Fourier-transform ion cyclotron resonance (FTICR) mass spectrometer 
A Fourier-transform ion cyclotron resonance (FT-ICR) mass spectrometer  
is a type of instrumentation that is considered one of the most complicated 
mass analysis and detection methods. Its m/z determination depends on the 
cyclotron frequency of an ion when a fixed magnetic field is applied (Figure 2) 
(207).  
When an ion is generated (in our experimental setting, the ions are 
produced with electrospray ionization), a series of pumping stages and an ion 
guide system lead the ions into the ICR cell where low pressure with a range of 
10-10 to 10-11 mBar is present (Figure 2A) (207). The ICR cell is surrounded by 
a spatial uniform static superconducting high field magnet (7 Tesla in our 
experimental setting), which is consistently cooled by liquid helium and liquid 
nitrogen in order to keep the temperature in the cell close to absolute zero 
(Figure 2A) (207). Due to the charge of the ion and the magnetic field, the ion 
moves in a cyclic motion in a plane perpendicular to the magnetic field due to 
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the Lorentz Force, and it is trapped in a Penning trap (Figure 2A) (207). With a 
certain magnetic field, the angular frequency of the ion is directly related to its 
m/Z value (Equation 1) (207). 
                         Equation 1 
in which B is the magnetic field strength (constant), ω is the induced cyclotron 
frequency, m is the mass of the ion, and Z is the charge on the ion. 
At this step, due to the small radius of the ion cycle motion, no signal can 
be detected (Figure 2B, left) (207). As demonstrated in Figure 2A, besides 
the trapping plates, two excitation plates are also installed at the sides of the 
ICR cell (207). By generating an oscillating electric field orthogonal to the 
magnetic field, the ions can be excited at their resonant frequencies to a higher 
radius (Figure 2B, middle) without affecting the cyclotron frequency (207). 
Excitation of each individual m/z can be achieved by a swept radio frequency 
pulse across the excitation plates of the cell (207). When the excited ion 
rotates at a higher orbit, an image current is induced and detected between the 
detection plates (Figure 2B, right and 2C) (207). The frequency of this current 
is the same as the cyclotron of the ion and the intensity is proportional to the 
number of ions (207). The resulting signal is called a free induction decay (FID) 
(207). The detected signal is then extracted by performing a Fourier 
transform to give a mass spectrum (Figure 2A) (207). Fourier transform ion 
cyclotron resonance (FTICR) mass spectrometry is a high resolution mass 
spectrometry technique with high accuracy. Due to its ion-trap nature, it does 
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not need to destroy the ions in order for the measurement to be performed. 
This enables further analysis on the desired ions. 
 
Figure 2. A schematic of the basic set up of an ICR trap configuration (A) and its 
detection mechanisms (B and C) are shown. (A) A schematic diagram of a cubic ICR cell 
is shown; (B) After the ions enter the ICR cell, they undergo excitation with a sweep RF 
and (C) induce a current in the detector plates (237, 238).  
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Quadruple ion trap (QIT) mass spectrometer 
Besides the FTICR mass spectrometer, another predominant instrument in 
the category of a trapping instrument is the quadrupole ion trap (QIT) mass 
spectrometer (205, 239). Compared to FTICR, a QIT mass spectrometer is a 
relatively inexpensive and simple bench-top instrument commonly used for 
routine applications. Its mass separation and detection mechanism is similar to 
FTICR, which results from the dynamic electric field (RF frequency) and is 
dependent on the m/Z value (205, 239).  
After ions are produced from the source (ESI source is used in our 
experimental setting), the ions enter the cell through the inlet (205, 239). The 
basic set up of a QIT cell is composed of three electrodes: one donut-shaped 
ring electrode is connected to radio frequency (RF) voltages, and two endcap 
electrodes are powered with direct current (DC) voltages (Figure 3A) (205, 
239). The combination of these electrodes results in a three-dimensional 
electric field and traps ions in the field (240). Similar to the FTICR, each m/z is 
directly related to a certain rf voltage (Figure 3B) (205, 239). By increasing the 
rf voltage, different m/z ions are excited separately (205, 239, 240). Under a 
certain rf voltage, the trajectories of the ions with corresponding m/z become 
unstable, which cause the ions to be ejected from the cell to strike a standard 
detector; meanwhile, those ions with stable trajectories are still trapped inside 
the electrodes (205, 239).  
Due to the high sensitivity, throughput, ease of use and low cost, the 
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quadrupole ion trap has become the workhorse for routine lab applications.  
 
Figure 3. A schematic of the basic set up of a QIT mass analyzer is shown. (A) The 
major components of a QIT analyzer are shown; (B) A schematic diagram of positively 
charged ions responding to the applied RF and DC field is given (205, 239, 240). 
Collision-induced dissociation (CID) 
CID is an effective fragmentation method used to induce the direct 
collision between a sample molecule with a rare gas atom in the cell (207, 208). 
Sample molecules dissociate as a result of the collision between a fast-speed 
sample and a neutral species (207, 208).  
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Figure 4. An analogy is given, illustrating a typical CID experiment (207, 208).  
As demonstrated in Figure 4, the target molecule will first be accelerated, 
also known as being "activated", and then it will enter the collision cell filled 
with the inert gas argon (207, 208). The target molecule will have multiple 
collisions with gas atoms, and the kinetic energy of the precursor will transfer 
to internal energy (207, 208). When the internal energy is accumulated enough 
to overcome the energy barrier, dissociation occurs (207, 208). The precursor 
breaks down from isomerization or direct breakage, and the resulting 
fragments are further captured by the detector (207, 208). In peptide-CID 
studies, the production of peptide fragments that only differ in a few amino 
acids occurs, providing sequencing information (241). This results in a gradual 
build-up of internal energy, and eventually causes the dissociation of parent 
ions. CID is the most used method in the tandem mass spectrometry analysis 
of peptides and proteins. 
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Infrared multiphoton dissociation (IRMPD) 
Infrared multiphoton dissociation (IRMPD) is also a powerful technique 
used in tandem mass spectrometry for the structural characterization of 
gaseous ions. Its mechanism is similar to the traditional infrared spectroscopy; 
however, it has higher sensitivity. This technique is normally implemented with 
trapping instrumentation, in which the isolated precursor ions are trapped and 
maintained in the laser beam for extended periods of time (208, 213). Similar 
to IR spectroscopy, the ions can absorb light of a certain wavelength (Figure 
5). After absorbing a photon, the ions are promoted to the absorbing mode 
from the ground state, and then the absorbed energy is redistributed to the 
vibrational degrees of freedom within the molecule via intramolecular 
vibrational relaxation (IVR) (Figure 5) (208, 213). IVR continuously 
depopulates the absorbing states and allows photon absorption to occur over 
and over again (Figure 5) (208, 213). This repeating process results in a 
gradual build up of internal energy, and eventually induces dissociation of the 
parent ions (Figure 5) (208, 213). The charged fragments are later detected 
with the second stage MS. Each MS/MS result from IRMPD technique is 
directly related to a certain wavelength IR laser. After plotting the extent of ion 
dissociation versus wavelength, the IRMPD spectrum is obtained (Figure 5). 
Normally, an intense laser source is used in this technique, such as a free 
electron laser, which is generated by projecting a high speed electron into a 
periodic magnetic structure (208, 213). 
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Figure 5. An schematic illustration is given, illustrating a typical IRMPD (208, 213).  
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ABSTRACT 
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The essential role of ribosomal RNA (rRNA) in the cell life cycle is 
highlighted by protein synthesis; therefore, the ribosome is considered to be an 
ideal drug target. Ribosomal RNAs exhibit a high level of structural diversity. 
The well-known anticancer drug cisplatin was previously applied as a chemical 
probe of rRNA structure to determine solvent accessible purines (guanosine) 
in vivo and in vitro. Cisplatin accumulates faster on RNA than DNA, with less 
chance of repair. As such, designing new RNA-targeting Pt compounds is not 
only a promising direction for chemical-probing applications, but also for the 
design of anticancer drugs that could overcome DNA repair-related resistance. 
In the present study, amino-acid-linked cisplatin analogues were synthesized. 
Their reactivity and product profiles with RNA were evaluated on the 
nucleoside level by using high performance liquid chromatography (HPLC), 
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nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry 
(MS). Tandem mass spectrometry (MS/MS) combined with computational 
chemistry was also utilized to assess the effects of Pt(II) on the 
glycosidic-bond strength of the purine nucleoside, and to obtain an 
atomic-level understanding of the nucleoside-Pt(II) products. Results reveal a 
cisplatin analogue with the first-reported template-independent adenosine 
preference, and demonstrate that Pt(II) reactivity can be tuned by altering the 
carrier ligand(s). This project also illustrates the potential of MS/MS to be used 
in RNA-Pt studies and provides details of adduct structures, such as the sites 
of adduct formation. 
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